Document:

EX-10.1

 Exhibit 10.1 
 EXECUTIVE EMPLOYMENT AGREEMENT 
 (Brian Roberts) 

This Executive Employment Agreement (the “Agreement”) is entered into on August 16, 2012 and is effective as of
July 30, 2012 (the “Effective Date”), by and between Grand Canyon Education, Inc., a Delaware corporation (the “Company”), and Brian Roberts (“Executive”). 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as
follows: 
 1. Employment. The Company desires to continue to employ Executive, and Executive desires to continue such
employment, upon the terms and conditions set forth herein. 
 2. Duties. 

2.1 Position. Executive is employed as Senior Vice President, General Counsel and Secretary and shall have the duties and
responsibilities reasonably assigned to him from time to time by the Company’s Chief Executive Officer (“CEO”). Executive shall perform faithfully and diligently all duties assigned to Executive. The Company reserves the right
to modify Executive’s position and duties at any time in its sole and absolute discretion, except that any material diminution in Executive’s duties shall be subject to Section 7.3(ii). 

2.2 Best Efforts/Full-time. Executive will expend Executive’s best efforts on behalf of the Company, and will abide by all
policies and decisions made by the Company, as well as all applicable federal, state and local laws, regulations or ordinances. Executive will act in the best interest of the Company at all times. Executive shall devote Executive’s full
business time and efforts to the performance of Executive’s assigned duties for the Company, unless Executive notifies the CEO in advance of Executive’s intent to engage in other paid work and receives the CEO’s express written
consent to do so. Notwithstanding the foregoing, Executive will be permitted to serve as an outside director on the board of directors for corporate, civic, nonprofit or charitable entities, so long as Executive obtains the consent of the CEO and
provided such entities are not competitive with the Company and subject to the provisions of Section 9. 
 2.3 Work
Location. Executive’s principal place of work shall be located in Phoenix, Arizona, or such other location as the Company may direct from time to time.  
 3. Term. 
 3.1 Initial Term. The employment relationship pursuant to
this Agreement shall be for an initial term commencing on the Effective Date and continuing for a period of four (4) years following such date (the “Initial Term”), unless sooner terminated in accordance with Section 7.

 3.2 Renewal. Upon expiration of the Initial Term and each Renewal Term, this Agreement will automatically renew for
subsequent one (1) year terms (each a “Renewal Term”) unless either party provides thirty (30) days’ advance written notice to the other that the Company or Executive does not wish to renew the Agreement for a
subsequent Renewal Term. In the event either party gives notice of nonrenewal pursuant to this Section 3.2, this Agreement will expire at the end of the then current term. The Initial Term and each subsequent Renewal Term are referred to
collectively as the “Term”. 

  
 1 

 4. Compensation. 

4.1 Base Salary. As compensation for Executive’s performance of Executive’s duties hereunder, effective beginning on the
Effective Date the Company shall pay to Executive an initial Base Salary at the rate of Two Hundred and Twenty-Five Thousand Dollars ($225,000) per year, payable in accordance with the normal payroll practices of the Company, less required
deductions for state and federal withholding tax, social security and all other employment taxes and payroll deductions. Executive’s Base Salary will be reviewed annually and adjustments, if any, will be made at that time. In the event
Executive’s employment under this Agreement is terminated by either party, for any reason, Executive will earn the Base Salary prorated to the date of termination, except as otherwise set forth herein. 

4.2 Incentive Compensation. Executive will be eligible to earn incentive compensation in the form of a semi-annual bonus for each
fiscal year of the Company, to be awarded under the Company’s cash incentive plan as then in effect, with a target amount equal to Thirty-Five Thousand Dollars ($35,000) per semi-annual period (the “Target Bonus”).
Executive’s Target Bonus will be reviewed annually and adjustments, if any, will be made at that time. The CEO will determine the actual amount of the bonus earned by Executive for any semi-annual period, which may be more or less than the
Target Bonus, and will base such determination upon both the Company’s achievement of overall performance metrics for the year and Executive’s achievement of individual performance metrics as agreed upon by the CEO and Executive. Earned
bonus amounts, if any, shall be paid within two and one-half months following the end of each semi-annual period. 
 4.3
Equity Awards. Executive will be eligible to receive stock, option or other equity awards (each, an “Equity Award”) under the Company’s applicable equity incentive plan as then in effect (the “Plan”), as
determined by the Compensation Committee. Any such Equity Award will be subject to the terms and conditions of the Plan and an applicable form of agreement for such Equity Award specified by the Compensation Committee, which Executive will be
required to sign as a condition of retaining the Equity Award. 
 5. Customary Fringe Benefits. Executive will be
eligible for all customary and usual fringe benefits generally available to senior management of the Company, subject to the terms and conditions of the Company’s benefit plan documents. The Company reserves the right to change or eliminate
fringe benefits on a prospective basis, at any time, effective upon notice to Executive. 
 6. Business Expenses.
Executive will be reimbursed for all reasonable, out-of-pocket business expenses incurred in the performance of Executive’s duties on behalf of the Company. To obtain reimbursement, expenses must be submitted promptly with appropriate
supporting documentation and will be reimbursed in accordance with the Company’s policies. Any reimbursement Executive is entitled to receive shall (a) be paid no later than the last day of Executive’s tax year following the tax year
in which the expense was incurred, (b) not affect or be affected by any other expenses that are eligible for reimbursement in any other tax year of Executive, and (c) not be subject to liquidation or exchange for another benefit.

  
 2 

 7. Termination of Executive’s Employment. 

7.1 Termination for Cause by Company. Although the Company anticipates the continuation of a mutually rewarding employment
relationship with Executive, the Company may terminate Executive’s employment immediately at any time for Cause. For purposes of this Agreement, “Cause” is defined as: (a) acts or omissions constituting gross negligence,
recklessness or willful misconduct on the part of Executive with respect to Executive’s obligations or otherwise relating to the business of the Company; (b) Executive’s material breach of this Agreement, including, without
limitation, any breach of Section 8, Section 9 or Section 11; (c) Executive’s breach of the Company’s Employee Nondisclosure and Assignment Agreement (the “Nondisclosure Agreement”);
(d) Executive’s conviction or entry of a plea of nolo contendere for fraud, misappropriation or embezzlement, or any felony or crime of moral turpitude; (e) Executive’s inability to perform the essential functions of
Executive’s position, with or without reasonable accommodation, due to a mental or physical disability; (f) Executive’s willful neglect of duties as determined in the sole and exclusive discretion of the CEO, provided that Executive
has received written notice of the action or omission giving rise to such determination and has failed to remedy such situation to the satisfaction of the CEO within thirty (30) days following receipt of such written notice, unless
Executive’s action or omission is not subject to cure, in which case no such notice shall be required, or (g) Executive’s death. In the event Executive’s employment is terminated in accordance with this Section 7.1,
Executive shall be entitled to receive only Executive’s Base Salary then in effect, prorated to the date of Executive’s termination of employment with the Company (the “Termination Date”), and all amounts and benefits
earned or incurred pursuant to Sections 5 and 6 through the Termination Date. All other Company obligations to Executive pursuant to this Agreement will be automatically terminated and completely extinguished as of the Termination Date, but
will be subject to the surviving provisions of this Agreement set forth in Section 13.8. Executive will not be entitled to receive the Severance Package described in Section 7.2. 

7.2 Termination Without Cause by Company. The Company may terminate Executive’s employment under this Agreement without Cause
at any time upon written notice to Executive. In the event of such termination, Executive will receive Executive’s Base Salary then in effect, prorated to the Termination Date, and all amounts and benefits earned or incurred pursuant to
Sections 5 and 6 through the Termination Date. In addition, subject to Sections 7.7 and 7.9, Executive will be entitled to receive a “Severance Package” that shall consist of: 

(a) severance in an amount equal to the sum of six (6) months of Executive’s Base Salary then in effect on the Termination
Date, with the total of such amount to be payable over six (6) months in equal installments in accordance with the Company’s regular payroll cycle, commencing with the first payroll date occurring on or after the 60th day following the
Termination Date; and 
 (b) payment by the Company of the premiums required to continue Executive’s group health care
coverage under the applicable provisions of the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”) for a period (the “COBRA Payment Period”) ending on the earlier of (i) six (6) months
following the Termination Date or (ii) the date on which Executive becomes eligible for health coverage through another employer, provided in any event that Executive timely elects to continue and remains eligible for these benefits under
COBRA. 

  
 3 

 Notwithstanding Section 7.2(b), if the Company determines, in its sole discretion, that the payment of
the COBRA premiums would result in a violation of the nondiscrimination rules of Section 105(h)(2) of the Internal Revenue Code of 1986, as amended (the “Code”), or any statute or regulation of similar effect (including but not
limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of providing the COBRA premiums, the Company, in its sole discretion, may elect to instead pay
Executive on the first day of each month of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premiums for that month, subject to applicable tax withholdings (such amount, the “Special Severance Payment,”
which shall be treated as part of the Severance Package), for the remainder of the COBRA Payment Period. Executive may, but is not obligated to, use such Special Severance Payment toward the cost of COBRA premiums. All other Company obligations to
Executive will be automatically terminated and completely extinguished, but will be subject to the surviving provisions of this Agreement set forth in Section 13.8. 
 7.3 Voluntary Resignation by Executive for Good Reason. Executive may voluntarily resign Executive’s position with the Company for Good Reason at any time on thirty (30) days’
advance written notice to the Company. In the event of Executive’s resignation for Good Reason, Executive will be entitled to receive Executive’s Base Salary then in effect, prorated to the Termination Date, and all amounts and benefits
earned or incurred pursuant to Sections 5 and 6 through the Termination Date. In addition, subject to Sections 7.7 and 7.9, Executive will be entitled to receive the Severance Package described in Section 7.2. All other Company
obligations to Executive pursuant to this Agreement will be automatically terminated and completely extinguished, but will be subject to the surviving provisions of this Agreement set forth in Section 13.8. Executive will be deemed to have
resigned for Good Reason if Executive voluntarily terminates his employment with the Company within ninety (90) days following the first occurrence of a condition constituting Good Reason. “Good Reason” means the occurrence of
any of the following conditions without Executive’s written consent, which condition(s) remain(s) in effect thirty (30) days after Executive provides written notice to the Company of such condition(s): (i) a material reduction in
Executive’s Base Salary as then in effect prior to such reduction, other than as part of a salary reduction program among similar management employees, (ii) a material diminution in Executive’s authority, duties or responsibilities as
an employee of the Company as they existed prior to such change, or (iii) a relocation of Executive’s principal place of work which increases Executive’s one-way commute distance by more than fifty (50) miles. Executive will be
deemed to have given consent to any condition(s) described in this Section 7.3 if Executive does not provide written notice to the Company of his intent to exercise his rights pursuant to this Section within thirty (30) days following the
first occurrence of such condition(s). 
 7.4 Voluntary Resignation by Executive Without Good Reason. Executive may
voluntarily resign Executive’s position with the Company without Good Reason at any time on thirty (30) days’ advance written notice to the Company. In the event of Executive’s resignation without Good Reason, Executive will be
entitled to receive only Executive’s Base Salary then in effect, prorated to the Termination Date, and all amounts and benefits earned or incurred pursuant to Sections 5 and 6 through the Termination Date. All other Company obligations to
Executive pursuant to this Agreement will be automatically terminated and completely extinguished. Executive will not be entitled to receive the Severance Package described in Section 7.2, but will be subject to the surviving provisions of this
Agreement set forth in Section 13.8. 

  
 4 

 7.5 Termination After a Change in Control. 

(a) Severance Payment; Equity Award Acceleration. If, upon or within twelve (12) months after a Change in Control (as that
term is defined below), Executive’s employment is terminated by the Company other than for Cause (as defined in Section 7.1) or Executive resigns for Good Reason (as defined in Section 7.3), then Executive shall be entitled to receive
Executive’s Base Salary then in effect, prorated to the Termination Date, and all amounts and benefits earned or incurred pursuant to Sections 5 and 6 through the Termination Date. In addition, subject to Sections 7.7 and 7.9,
Executive will be entitled to receive (i) the Severance Package described in Section 7.2 and (ii) to the extent not yet vested, but subject to the terms of any agreement governing any such Equity Award, any outstanding Equity Awards
granted to Executive by the Company shall vest in full as of the Termination Date. All other Company obligations to Executive pursuant to this Agreement will be automatically terminated and completely extinguished as of the Termination Date, but
will be subject to the surviving provisions of this Agreement set forth in Section 13.8. 
 (b) Parachute Payments.

 (i) Notwithstanding any provision of this Agreement to the contrary, if any payment or benefit Executive would receive
pursuant to this Agreement or otherwise (collectively, the “Payments”) would constitute a “parachute payment” within the meaning of Section 280G of the Code, and, but for this sentence, would be subject to the excise
tax imposed by Section 4999 of the Code or any similar or successor provision (the “Excise Tax”), then the aggregate amount of the Payments will be either (i) the largest portion of the Payments that would result in no
portion of the Payments (after reduction) being subject to the Excise Tax or (ii) the entire Payments, whichever amount after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all
computed at the highest applicable marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such state and local taxes), results in Executive’s receipt, on an after-tax basis, of the
greatest amount of the Payments. Any reduction in the Payments required by this Section will be made in the following order: (A) reduction of cash payments; (B) reduction of accelerated vesting of Equity Awards other than stock options;
(C) reduction of accelerated vesting of stock options; and (D) reduction of other benefits paid or provided to Executive. In the event that acceleration of vesting of Equity Awards is to be reduced, such acceleration of vesting will be
cancelled in the reverse order of the date of grant of such Equity Awards. If two or more Equity Awards are granted on the same date, the accelerated vesting of each award will be reduced on a pro-rata basis. 

(ii) The professional firm engaged by the Company for general tax purposes as of the day prior to the date of the event that might
reasonably be anticipated to result in Payments that would otherwise be subject to the Excise Tax will perform the foregoing calculations. If the tax firm so engaged by the Company is serving as accountant or auditor for the acquiring company, the
Company will appoint a nationally recognized tax firm to make the determinations required by this Section. The Company will bear all expenses with respect to the determinations by the tax firm required to be made by this Section. The Company and
Executive shall furnish the tax firm such information and documents as the tax firm may reasonably request in order to make its required determination. The tax firm will provide its calculations, together with detailed supporting documentation, to
the Company and Executive as soon as practicable following its engagement. Any good faith determinations of the tax firm made hereunder will be final, binding and conclusive upon the Company and Executive. 

  
 5 

 (c) Change in Control. A Change in Control is defined as any one of the following
occurrences: 
 (i) Any “person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange
Act of 1934 (the “Exchange Act”)), becomes the “beneficial owner” (as such term is defined in Rule 13d-3 promulgated under the Exchange Act), directly or indirectly, of securities of the Company representing more than
fifty percent (50%) of the total fair market value or total combined voting power of the Company’s then-outstanding securities entitled to vote generally in the election of directors; provided, however, that a Change in Control shall not
be deemed to have occurred if such degree of beneficial ownership results from any of the following: (A) an acquisition of securities by any person who on the Effective Date is the beneficial owner of more than fifty percent (50%) of such
voting power, (B) any acquisition of securities directly from the Company, including, without limitation, pursuant to or in connection with a public offering of securities, (C) any acquisition of securities by the Company, (D) any
acquisition of securities by a trustee or other fiduciary under an employee benefit plan of the Company, or (E) any acquisition of securities by an entity owned directly or indirectly by the stockholders of the Company in substantially the same
proportions as their ownership of the voting securities of the Company; or 
 (ii) the sale or disposition of all or
substantially all of the Company’s assets (other than a sale or disposition to one or more subsidiaries of the Company), or any transaction having similar effect is consummated; or 

(iii) the Company is party to a merger or consolidation that results in the holders of voting securities of the Company outstanding
immediately prior thereto failing to continue to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than 50% of the combined voting power of the voting securities of the Company or
such surviving entity outstanding immediately after such merger or consolidation; or 
 (iv) the dissolution or liquidation of
the Company. 
 7.6 Termination of Employment Upon Nonrenewal. In the event either party decides not to renew this
Agreement for a subsequent term in accordance with Section 3.2, this Agreement will expire automatically upon completion of the then effective Term, and Executive’s employment with the Company will thereupon terminate. Executive will be
entitled to receive only Executive’s Base Salary then in effect, prorated to the Termination Date, and all amounts and benefits earned or incurred pursuant to Sections 5 and 6 through the Termination Date. All other Company obligations to
Executive pursuant to this Agreement will be automatically terminated and completely extinguished. Executive will not be entitled to receive the Severance Package described in Section 7.2, but will be subject to the surviving provisions of this
Agreement as set forth in Section 13.8. 
 7.7 Conditions to Severance Package. Executive will only be entitled to
receive the Severance Package if, on or before the 60th day following the Termination Date, Executive executes a full general release, releasing all claims, known or unknown, that Executive may have against the Company and its officers, directors,
employees and affiliated companies arising out of or any way related to Executive’s employment or termination of employment with the Company, and the period for revocation, if any, of such release has lapsed without the release having been
revoked. In the event that Executive breaches any of the covenants contained in Sections 9 (“Other Covenants”), 10 (“Confidentiality and Proprietary Rights”) or 11 (“Non-Competition; Nonsolicitation of Company
Employees”), the Company shall have the right to (a) terminate further provision of any portion of the Severance Package not yet paid or provided, and (b) seek reimbursement from Executive for any and all portions of the Severance
Package previously paid or provided to Executive. 

  
 6 

 7.8 Resignation of Board or Other Positions. Executive agrees that should
Executive’s employment terminate for any reason, Executive will immediately resign all other positions (including board membership) Executive may hold on behalf of the Company. 

7.9 Application of Section 409A. 
 (a) Notwithstanding anything set forth in this Agreement to the contrary, no amount payable pursuant to this Agreement on account of Executive’s termination of employment with the Company which
constitutes a “deferral of compensation” within the meaning of the Treasury Regulations issued pursuant to Section 409A of the Code (the “Section 409A Regulations”) shall be paid unless and until Executive has
incurred a “separation from service” within the meaning of the Section 409A Regulations. Furthermore, if Executive is a “specified employee” within the meaning of the Section 409A Regulations as of the date of
Executive’s separation from service, no amount that constitutes a deferral of compensation which is payable on account of Executive’s separation from service shall be paid to Executive before the date (the “Delayed Payment
Date”) which is first day of the seventh month after the date of Executive’s separation from service or, if earlier, the date of Executive’s death following such separation from service. All such amounts that would, but for this
Section 7.9(a), become payable prior to the Delayed Payment Date will be accumulated and paid on the Delayed Payment Date. 
 (b) It is the intent of the Company and Executive that any right of Executive to receive installment payments hereunder shall, for all purposes of Section 409A of the Code, be treated as a right to a
series of separate payments. 
 (c) The Company intends that income provided to Executive pursuant to this Agreement will not
be subject to taxation under Section 409A of the Code. The provisions of this Agreement shall be interpreted and construed in favor of satisfying any applicable requirements of Section 409A of the Code. However, the Company does not
guarantee any particular tax effect for income provided to Executive pursuant to this Agreement. In any event, except for the Company’s responsibility to withhold applicable income and employment taxes from compensation paid or provided to
Executive, the Company shall not be responsible for the payment of any applicable taxes incurred by Executive on compensation paid or provided to Executive pursuant to this Agreement. 

8. No Violation of Rights of Third Parties. Executive represents and warrants to the Company that Executive is not currently a
party, and will not become a party, to any other agreement that is in conflict with, or will prevent Executive from complying with, this Agreement. Executive further represents and warrants to the Company that Executive’s performance of all of
the terms of this Agreement as an employee of the Company does not and will not breach any agreement to keep in confidence any proprietary information, knowledge, or data acquired by Executive in confidence or trust prior to Executive’s
employment with the Company. Executive acknowledges and agrees that the representations and warranties in this Section 8 are a material part of this Agreement. 

  
 7 

 9. Other Covenants. Executive hereby makes the following covenants, each of which
Executive acknowledges and agrees are a material part of this Agreement: 
 9.1 During the Term, Executive will not
(a) breach any agreement to keep in confidence any confidential or proprietary information, knowledge or data acquired by Executive prior to Executive’s employment with Company, or (b) disclose to the Company, or use or induce the
Company to use, any confidential or proprietary information or material belonging to any previous employer or any other third party. Executive acknowledges that the Company has specifically instructed Executive not to breach any such agreement or
make any such disclosures to the Company. 
 9.2 During the Term, Executive will not engage in any work or activity, paid or
unpaid, that creates an actual conflict of interest with the Company. Such work shall include, but is not limited to, directly or indirectly competing with the Company in any way, or acting as an officer, director, employee, consultant, stockholder,
volunteer, lender, or agent of any business enterprise of the same nature as, or which is in direct competition with, the business in which the Company is now engaged or in which the Company becomes engaged during the Term, as may be determined by
the Company in its sole discretion. If the Company believes such a conflict exists during the Term, the Company may ask Executive to choose to discontinue the other work or activity or resign employment with the Company. 

9.3 During the Term and after the termination thereof, neither Executive nor the Company will disparage each other, or the Company’s
products, services, agents or employees. 
 9.4 During the Term and after the termination thereof, at the Company’s expense
and upon its reasonable request, Executive will cooperate and assist the Company in its defense or prosecution of any disputes, differences, grievances, claims, charges, or complaints between the Company and any third party, which assistance will
include testifying on the Company’s behalf in connection with any such matter or performing any other task reasonably requested by the Company in connection therewith. 
 10. Confidentiality and Proprietary Rights. Executive agrees to continue to abide by the Nondisclosure Agreement, which is incorporated herein by reference. 

11. Non-Competition; Nonsolicitation of Company’s Employees. Executive acknowledges that in the course of his employment with
the Company he will serve as a member of the Company’s senior management and will become familiar with the Company’s trade secrets and with other confidential and proprietary information and that his services will be of special, unique and
extraordinary value to the Company. Executive further acknowledges that the Company’s business, a substantial portion of which is conducted online, is national in scope and that the Company, in the course of such business, recruits students and
faculty throughout the United States, works with vendors throughout the United States, and competes with other companies located throughout the United States. Therefore, in consideration of the foregoing, Executive agrees that, during the Term, and
during the six-month (6) month period following the Term, he shall not directly or indirectly anywhere within the United States of America (a) own (except ownership of less than 1% of any class of securities which are listed for
trading on any securities exchange or which are traded in the over-the-counter market), manage, control, participate in, consult with, render services for, be employed by, or in any manner engage in the operation of (i) a for-profit,
post-secondary education institution, or (ii) any other business of the Company in which Executive had significant involvement prior to Executive’s separation; (b) solicit funds on behalf of, or for the benefit of, any for-profit,
post-secondary education institution (other than the Company) or any other entity that competes with the Company; (c) solicit individuals who are current or prospective students of the Company to be students for any other for-profit,
post-secondary education institution; (d) induce or attempt to induce any employee of the Company to leave the employ of the Company, or in any way interfere with the relationship between the Company and any employee thereof, or (e) induce
or attempt to induce any student, customer, supplier, licensee or other business relation of the Company to cease doing business with, or modify its business relationship with, the Company, or in any way interfere with or hinder the relationship
between any such student, customer, supplier, licensee or business relation and the Company. 

  
 8 

 12. Injunctive Relief. Executive acknowledges that Executive’s breach of the
covenants contained in Sections 9, 10 and 11 hereof (collectively “Covenants”) would cause irreparable injury to the Company and agrees that in the event of any such breach, the Company shall be entitled to seek temporary,
preliminary and permanent injunctive relief without the necessity of proving actual damages or posting any bond or other security in addition to any other relief to which the Company may be entitled and other remedies Company may exercise under this
Agreement or otherwise. 
 13. General Provisions. 

13.1 Successors and Assigns. The rights and obligations of the Company under this Agreement shall inure to the benefit of and
shall be binding upon the successors and assigns of the Company. Executive shall not be entitled to assign any of Executive’s rights or obligations under this Agreement. 
 13.2 Waiver. Either party’s failure to enforce any provision of this Agreement shall not in any way be construed as a waiver of any such provision, or prevent that party thereafter from
enforcing each and every other provision of this Agreement. 
 13.3 Attorneys’ Fees. In the event of a dispute
involving the interpretation or enforcement of this Agreement, a court shall award attorneys’ fees and costs to the prevailing party. 
 13.4 Severability. In the event any provision of this Agreement is found to be unenforceable by a court of competent jurisdiction, such provision shall be deemed modified to the extent necessary to
allow enforceability of the provision as so limited, it being intended that the parties shall receive the benefit contemplated herein to the fullest extent permitted by law. If a deemed modification is not satisfactory in the judgment of such court,
the unenforceable provision shall be deemed deleted, and the validity and enforceability of the remaining provisions shall not be affected thereby. 
 13.5 Interpretation; Construction. The headings set forth in this Agreement are for convenience only and shall not be used in interpreting this Agreement. This Agreement has been drafted by legal
counsel representing the Company, but Executive has participated in the negotiation of its terms. Furthermore, Executive acknowledges that Executive has had an opportunity to review and revise the Agreement and have it reviewed by legal counsel, if
desired, and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement. 

  
 9 

 13.6 Governing Law; Forum. This Agreement will be governed by and construed in
accordance with the laws of the United States and the State of Arizona . Each party consents to the jurisdiction and venue of the state or federal courts in Phoenix, Arizona, if applicable, in any action, suit, or proceeding arising out of or
relating to this Agreement, and agrees that the state or federal courts in Phoenix, Arizona shall have exclusive jurisdiction over any dispute arising between the parties related to this Agreement or Executive’s employment with the Company.

 13.7 Notices. Any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows
with notice deemed given as indicated: (a) by personal delivery when delivered personally; (b) by overnight courier upon written verification of receipt; (c) by telecopy or facsimile transmission upon acknowledgment of receipt of
electronic transmission; or (d) by certified or registered mail, return receipt requested, upon verification of receipt. Notice shall be sent to the addresses set forth under the signatures below, or such other address as either party may
specify in writing. 
 13.8 Survival. Sections 9 (“Other Covenants”), 10 (“Confidentiality
and Proprietary Rights”), 11 (“Non-Competition; Nonsolicitation of Company’s Employees”), 12 (“Injunctive Relief”), 14 (“General Provisions”) and 15 (“Entire Agreement”) of this
Agreement shall survive termination of Executive’s employment with the Company. 
 14. Entire Agreement. This
Agreement, including the Nondisclosure Agreement incorporated herein by reference, constitutes the entire agreement between the parties relating to this subject matter and supersedes all prior or simultaneous representations, discussions,
negotiations, and agreements, whether written or oral. This Agreement may be amended or modified only with the written consent of Executive and the Board. No oral waiver, amendment or modification will be effective under any circumstances
whatsoever. 
 THE PARTIES TO THIS AGREEMENT HAVE READ THE FOREGOING AGREEMENT AND FULLY UNDERSTAND EACH AND EVERY PROVISION CONTAINED HEREIN.
WHEREFORE, THE PARTIES HAVE EXECUTED THIS AGREEMENT ON THE DATES SHOWN BELOW. 
  

							
		 		 	BRIAN ROBERTS
				
	Dated: August 16, 2012	 		 	By:	 	/s/ Brian M. Roberts
		 		 	Address:	 	3300 West Camelback Road
		 		 		 	Phoenix, Arizona 85017
			
		 		 	GRAND CANYON EDUCATION, INC.
				
	Dated: September 7, 2012	 		 	By:	 	/s/ Brian E. Mueller
		 		 	Name:	 	Brian E. Mueller
		 		 	Title:	 	CEO and Director
				
		 		 	Address:	 	3300 West Camelback Road
		 		 		 	Phoenix, Arizona 85017

  
  

 

  
 10EX-10.1

 EXECUTION COPY 

Exhibit 10.1 

BIOPROCESSING SERVICES AGREEMENT 
 This Bioprocessing Services Agreement dated January 22, 2013 (this “Agreement”) between Synageva BioPharma Corp., a Delaware corporation (“Sponsor”) having its
principal place of business at 128 Spring Street, Suite 520, Lexington, Massachusetts 02421 and FUJIFILM Diosynth Biotechnologies U.S.A., Inc., a Delaware corporation (“Diosynth”), having its principal place of business at 101 J.
Morris Commons Lane, Morrisville, NC 27560, (each a “Party”, collectively, the “Parties”). 
 Sponsor desires
Diosynth to perform services in accordance with the terms of this Agreement and the Scope (as hereinafter defined) related to the production of the material as described in the relevant Scope of Work (“Product”) and Diosynth desires
to perform such services; 
 In consideration of the above statements, which form part of this Agreement, and other good and valuable
consideration, the sufficiency and receipt of which are hereby acknowledged, the Parties hereto agree as follows: 
 Definitions:

 “Agreement” shall have the meaning set forth in the preamble. 
 “Alliance Manager” shall have the meaning set forth in Section 21(b). 

“Assumptions” shall have the meaning set forth in Section 6(a). 
 “Batch Packet” shall mean a compilation of records, including but not limited to, executed process records, genealogy, certificate of analysis (“COA”) and associated
Quality Control data, [*] Deviation Reports, Disposition of Product form, Restriction Summary and Facility Assessment memo. 

“cGMP” shall have the meaning set forth in Section 3(a). 
 “Change Order” shall have the meaning set forth in Section 6(b). 

“Claim” shall have the meaning set forth in Section 15(a). 
 “Confidential Information” shall have the meaning set forth in Section 7(d). 

“Diosynth Confidential Information” shall have the meaning set forth in Section 7(b). 

“Diosynth Factor” shall mean (a) Diosynth’s negligence or willful default or inaction,
(b) Diosynth’s failure to comply with cGMP, or (c) the failure of the GMP Facility to comply with applicable laws.  
 “Facilities” shall mean Diosynth’s facilities located in North Carolina, including the GMP manufacturing plant (“GMP Facility”), the process development
laboratories, the GMP warehouse, and the administrative building. 
 “Impasse Notice” shall have the meaning set forth in
Section 6(b). 
  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Securities and
Exchange Commission.

 “Indemnified Party” shall have the meaning set forth in Section 15(c). 

“Indemnity Claim” shall have the meaning set forth in Section 15(c). 
 “Joint Steering Committee” shall have the meaning set forth in Section 21(a). 
 “Loss” shall have the meaning set forth in Section 15(a). 

“Modification” shall have the meaning set forth in Section 6(a). 
 “Non-Conforming Batch” shall mean a cGMP Batch which: (i) has not been produced in accordance with cGMP; and/or (ii) does not meet the Product specification set out in the
Product item specification. 
 “Party” or “Parties” shall have the meaning set forth in the preamble. 

“Process Consumables” shall have the meaning set forth in the Scope. 
 “Process Invention” shall have the meaning set forth in Section 9(b). 

“Product” shall have the meaning set forth in the preamble. 
 “Product Invention” shall have the meaning set forth in Section 9(b). 

“Program” shall mean the services to be performed under this Agreement. 
 “Program Invention” shall have the meaning set forth in Section 9(a). 

“Program Price and Payment Schedule” shall mean the schedule attached as Appendix 3 to this Agreement. 

“Quality Agreement” shall mean the quality agreement attached as Appendix 2 to this Agreement. 

“Regulatory Authority” shall mean any national, regional, state or local regulatory agency, department, bureau, commission, council or
other governmental entity with authority over the Manufacture, production, use or storage, transport, clinical testing, marketing, pricing or sale of Product, including the United States Food and Drug Administration (the “FDA”) or
any successor agency or authority thereto, and the European Medicines Agency (the “EMA”), or any successor agency or authority thereto. 
 “Scope” shall mean the scope of work attached as Appendix 1 to this Agreement. 

“Sponsor” shall have the meaning set forth in the preamble. 
 “Sponsor Deliverables” shall have the meaning set forth in the Scope. 

“Sponsor Confidential Information” shall have the meaning set forth in Section 7(a). 

“Term” shall have the meaning set forth in Section 20(a). 
 “Work Output” shall have the meaning set forth in Section 8(a). 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	2

 Section 1. 
 Scope of Work/Performance of Program 
  

	 	a)	Diosynth will perform the Program for Sponsor in accordance with the terms and conditions of this Agreement, the Scope (attached as Appendix 1) and the Quality
Agreement (attached as Appendix 2). Terms defined in the terms and conditions of this Agreement and the Scope and/or Quality Agreement shall have same meaning when used in the Scope or Quality Agreement. In the event of any conflict among the
components of this Agreement and the Scope and/or Quality Agreement, the following order of precedence shall apply: 

  

	 	1.	the terms and conditions of this Agreement; 

  

	 	2.	the Quality Agreement; and 

  

	 	3.	the Scope. 

  

	 	b)	Sponsor shall perform its obligations as set forth in this Agreement (including the Scope) and the Quality Agreement, shall support and cooperate with the execution of
the Program and shall not engage, or fail to engage, in any act, which may reasonably be expected to prevent or delay the successful execution of the Program. 

 Section 2. 
 Sponsor Deliverables 

 

	 	a)	As further set forth in the Scope, Sponsor will timely provide Diosynth with Sponsor Deliverables (as defined in the Scope) at the Facilities. Sponsor acknowledges that
the failure by Sponsor to provide Sponsor Deliverables within the timeframe set forth in the Scope may result in additional charges to Sponsor and a delay in meeting Program objectives. 

 

	 	b)	Title to Sponsor Deliverables shall remain with Sponsor. Diosynth shall not sell, pledge, hypothecate, dispose of, or otherwise transfer any interest in Sponsor
Deliverables except as otherwise provided in this Agreement, and shall use Sponsor Deliverables solely for purposes of performing the Program. Diosynth shall provide safe and secure storage conditions at the Facilities for Sponsor Deliverables while
they are at the Facilities, shall store the Sponsor Deliverables in accordance with all applicable statutory and regulatory requirements and any storage guidelines provided by Sponsor and agreed upon by Diosynth and, upon termination of this
Agreement, at the instruction of Sponsor, either return or destroy any unused Sponsor Deliverables at Sponsor’s expense. 

Section 3. 
 Compliance with
Government Regulations 
  

	 	a)	 Diosynth shall operate the GMP Facility as a compliant current Good Manufacturing Practices (“cGMP”) facility in accordance with 21
CFR Parts 11, 210, 211, 600, & 610, ICH Q7 GMP Guidance for Active Pharmaceutical Ingredients, and the EU GMP Guide, including any requirements provided for in the Quality Agreement for all aspects of manufacturing, testing, holding,
packaging, labeling and delivery of the Product and/or intermediates produced for Sponsor. In addition, Diosynth shall perform the Program in compliance with statutory and regulatory requirements applicable to the Product’s clinical phase,
including any other applicable regulations and/or guidance documents promulgated by any applicable Regulatory Authority. Diosynth shall not permit debarred 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	3

	 	
persons to participate in the Program. Diosynth shall undertake reasonable steps to prevent such participation. If Diosynth becomes aware of the debarment or threatened debarment of any person
participating in the Program, Diosynth shall promptly so notify Sponsor. 

  

	 	b)	Sponsor acknowledges that Diosynth has consulted with Sponsor in designing the Program in a manner consistent with current applicable regulatory guidelines.
Notwithstanding the foregoing, except as set forth in Section 3(a), Diosynth does not warrant that the Program and/or the Program results will satisfy the requirements of any Regulatory Authority at the time of submission of Program results to
such Regulatory Authority. As between the Parties, (i) Sponsor shall have the sole right and responsibility for determining regulatory strategy, decision and actions relating to the Program and the Product and, (ii) subject to each
Party’s contractual obligations under this Agreement, Diosynth shall have the sole right and responsibility for determining regulatory strategy, decision and actions to the extent relating to (A) the Facilities; (B) Diosynth’s
quality systems; or (iii) any requirement imposed on Diosynth by a Regulatory Authority. Diosynth hereby represents that, to Diosynth’s knowledge, as of the Effective Date, no requirement imposed on Diosynth by a Regulatory Authority or
any other commitments made by Diosynth shall delay or prevent Diosynth from performing the Program or otherwise complying with its obligations hereunder. 

  

	 	c)	Should such applicable regulatory requirements change, Diosynth will promptly notify Sponsor of such change and the effect on the Program and Diosynth will use
reasonable efforts to satisfy the new requirements. In the event that compliance with such new applicable regulatory requirements necessitates a change in the Scope, Diosynth will submit to Sponsor a Change Order, as herein after defined, in
accordance with Section 6 of this Agreement. 

  

	 	d)	Subject to this Section 3, in the event of a conflict in government regulations applicable to the performance of the Program, Sponsor and Diosynth will agree in
good faith as to which regulations shall be followed by Diosynth in its performance of the Program. 

  

	 	e)	If Diosynth receives any contact or communication from any Regulatory Authority relating in any way to the Program, Diosynth will (i) notify Sponsor and provide
Sponsor with copies of any such communication within two (2) business days of its receipt of such communication and (ii) comply with all reasonable requests by Sponsor with respect to any actions to be taken or responses to be made to any
such Regulatory Authority. Diosynth will promptly inform Sponsor in the event that any such Regulatory Authority takes any action against Diosynth for any reason that could be reasonably be expected to have an effect on Diosynth’s performance
of the Program. Unless required by applicable laws or regulations, Diosynth will have no contact or communication with any such Regulatory Authority regarding the Product without the prior written consent of Sponsor, which consent will not be
unreasonably withheld.  

  

	 	f)	Diosynth shall secure and maintain in good order, at its sole cost and expense, such current governmental registrations, permits and licenses as are required by any
Regulatory Authority in order for Diosynth to perform its obligations under this Agreement. 

  

	 	g)	If Diosynth receives notice of action or threat of action with respect to its debarment during the Term of this Agreement (i) Diosynth shall so notify Sponsor
immediately and (ii) Sponsor shall have the right to terminate this Agreement upon not less than ten (10) days’ written notice. 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	4

 Section 4. 
 Facility Visits 
 The terms and conditions of Sponsor audit rights and rights to
visit and inspect the Facilities are provided in the Quality Agreement. 
 Section 5. 

Compensation 
  

	 	a)	Sponsor shall make the payments to Diosynth set forth in, and in accordance with, the Program Price and Payment Schedule. In addition, pursuant to the Scope, Sponsor
agrees to pay Diosynth [*] for any Process Consumables purchased for the Program pursuant to the terms set forth in the Scope plus a fee equal [*] of such [*]. These amounts will be invoiced separately as they are incurred by Diosynth. Within thirty
(30) days of completion of all Manufacturing under this Agreement, Sponsor will provide Diosynth with written notice specifying its preferred method of disposition for any remaining Process Consumables, the costs for which shall be borne solely
by Sponsor. In specifying its preferred method for such disposition, Sponsor may choose from the following three options: 

  

	 	1.	having Diosynth deliver remaining Process Consumables to Sponsor or a designated storage site; 

 

	 	2.	having Diosynth deliver remaining Process Consumables to a destruction site; or 

 

	 	3.	assigning ownership of remaining Process Consumables to Diosynth at no cost. 

 In the event that Sponsor fails to provide written notice of its preferred method of disposition to Diosynth within the above thirty (30) day period, Diosynth will implement the second option
specified above, the costs for which shall be borne solely by Sponsor. 
  

	 	b)	Subject to Section 5(d), payments are due thirty (30) calendar days from the date any invoice issued by Diosynth is received by Sponsor consistent with the
Program Price and Payment Schedule. Unless Sponsor has advised Diosynth in good faith and in writing the specific basis for disputing an invoice, failure to pay an invoice within [*] from the date of invoice receipt may, at Diosynth’s election,
constitute a material breach of this Agreement. Invoices will include a summary of all activities completed during the invoice period and a description of all Process Consumables purchased during the invoice period. 

 

	 	c)	 Diosynth has allocated resources to the Program that may be difficult or impractical to reallocate to other programs in the event of a material delay
in the conduct of the Program that is reasonably attributable to Sponsor (a “Sponsor Delay”). In recognition of this, upon the occurrence of a Sponsor Delay, (i) Sponsor shall provide Diosynth with prompt written notice of
same, (ii) Diosynth shall use reasonable efforts to reallocate resources to other programs and Sponsor and Diosynth shall negotiate in good faith a Change Order to compensate Diosynth for any idled personnel or capacity it is unable to
reasonably reallocate to such other programs; and (iii) subject to subsection (ii), Sponsor agrees to pay the amounts set forth in and in accordance with the Change Order during such Sponsor Delay, including for completion of any components of
the Program that are so delayed and not reallocated, for a period of [*]. Notwithstanding the foregoing, if Sponsor provides a notice of the occurrence of a Sponsor Delay within [*] prior to the scheduled commencement date for manufacturing
activities and Diosynth is unable to reasonably reallocate the resources to be used in the Program to other programs, then (i) as 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	5

	 	
Diosynth’s sole remedy for such Sponsor Delay, Sponsor shall pay Diosynth, upon receipt of Diosynth’s invoice, the following amounts: (A) if the notice of the occurrence of the
Sponsor Delay is delivered by Sponsor on or between [*] and [*] days from the scheduled commencement date for manufacturing activities, an amount equal to [*] of the unbilled activities under the Manufacturing heading in the Program Price and
Payment Schedule; (B) if the notice of the occurrence of the Sponsor Delay is delivered by Sponsor on or between [*] and [*] days from the scheduled commencement date for manufacturing activities, an amount equal to [*] of the unbilled
activities under the Manufacturing heading in the Program Price and Payment Schedule; and (C) if the notice of the occurrence of a Sponsor Delay is delivered by Sponsor less than [*] from the scheduled commencement date for manufacturing
activities, an amount equal to [*] of the unbilled activities under the Manufacturing heading in the Program Price and Payment Schedule; and (ii) Diosynth shall prepare in good faith and promptly provide to Sponsor a reasonable rescheduled date
for the commencement of Sponsor manufacturing activities. Notwithstanding the foregoing, Sponsor Delays resulting in delays to commencement of manufacturing activities of [*] or more from the originally scheduled commencement date for such
manufacturing activities shall be subject to the cancellation payments equal to [*] described in [*], less any delay payments already made by Sponsor. 

  

	 	d)	Diosynth shall (i) use commercially reasonable efforts to complete disposition of each cGMP batch of Product (each, a “Batch”) within the period
specified in the Quality Agreement, and (ii) provide Sponsor’s quality assurance department with a Batch Packet within ten (10) days of completion of disposition of each such Batch by Diosynth and (if appropriate) a recommendation for
such Batch to be released. Within thirty (30) days after Sponsor’s receipt of such documentation, Sponsor shall review the Batch Packet to determine, to the extent ascertainable from such documentation, whether or not the Batch of Product
covered by such Batch Packet conforms to the specifications set forth in the agreed specifications.  

  

	 	e)	The following provisions shall apply if during disposition of a cGMP Batch or as a result of Sponsor’s review of the applicable Batch Packet, it is ascertained by
either Party that such Batch is a Non-Conforming Batch: 

  

	 	(i)	Diosynth or Sponsor, as the case may be, shall provide written notice of same to the other Party. 

 

	 	(ii)	The Non-Conforming Batch shall not be delivered to Sponsor. 

  

	 	(iii)	Diosynth shall use commercially reasonable efforts to manufacture a further Batch to replace the Non-Conforming Batch. 

 

	 	(1)	If the Non-Conforming Batch arose other than as a result of a Diosynth Factor: 

 

	 	(A)	Subject to Section 5(g), Sponsor shall be obliged to make payment for such Non-Conforming Batch in accordance with Section 5 and the applicable Program Price
and Payment Schedule. 

  

	 	(B)	If Sponsor wishes Diosynth to carry out additional work under the Program with respect to such Non-Conforming Batch, such additional work, including further
manufacture, shall be carried out at a time to be agreed and subject to agreement of the price payable in respect of such further manufacture, such agreement to be recorded in a Change Order. 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	6

	 	(2)	If the Non-Conforming Batch arose as a result of a Diosynth Factor, Diosynth shall undertake the manufacture of a further Batch under Section 5(e)(iii) to replace
the Non-Conforming Batch at Diosynth’s cost and expense and as soon as reasonably practicable.  

  

	 	(iv)	Unless otherwise agreed by the Parties in writing, Diosynth shall dispose of any Non-Conforming Batch that Diosynth is obligated to replace pursuant to
Section 5(e)(iii) in accordance with all applicable laws, and such disposal shall be at Diosynth’s cost, if Diosynth was liable for the Non-Conforming Batch in accordance with Section 5(e)(iii)(2), and at Sponsor’s cost
otherwise. 

 Notwithstanding the foregoing, should any hidden or latent defects be discovered after the delivery
of a Batch but in no event after [*] from the date the Batch is delivered, which defects could not reasonably be discovered during disposition within that period, then Sponsor shall promptly inform Diosynth. In the event that the Batch fails to
comply with agreed upon specifications, and it is agreed by the Parties or established under the mechanism set out in Section 5(g) below that such failure was due to a Diosynth Factor, then Sponsor shall be entitled to the remedies under
Section 5(e)(iii)(2) and (iv). 
 Notwithstanding anything to the contrary in this Agreement, the remedies set out in this
Section 5(e) shall be Sponsor’s sole remedies in relation to a Non-Conforming Batch. 
 For the avoidance of doubt, if
the Parties agree that an [*] Batch under a Scope of Work is to be carried out in accordance with cGMP, such [*] Batch shall not be treated as a GMP Batch for the purposes of this Section 5. 

 

	 	f)	If following the review of Batch Packet, it is ascertained by agreement of the Parties (or in the absence of such agreement, through arbitration pursuant to
Section 14) that the Batch conforms to the specifications set forth in the agreed specifications and otherwise complies with the representations, warranties and covenants in Section 16(d) (a “Conforming Batch”), then
Sponsor shall issue to Diosynth a certificate of compliance and Diosynth shall have no liability to Sponsor pursuant to Section 5(e)(iii) with respect to such Conforming Batch, and Sponsor shall pay for such Conforming Batch pursuant to
Section 5. 

  

	 	g)	In the event the Parties disagree in good faith as to whether a Batch of Product is a Conforming Batch or Non-Conforming Batch, the Parties shall agree to submit
test samples for analysis to a mutually agreed upon independent third party GMP laboratory which is able to provide laboratory equipment and personnel that are qualified in the same manner as the Sponsor/ Diosynth facilities. The Parties hereby
agree that a formal method transfer and qualification/validation must be completed by the third party laboratory prior to performing any testing related to a dispute resolution under Section 14. The costs of such independent laboratory shall be
borne [*]; provided, however, that the Party that is determined to be correct in the dispute, shall be reimbursed by the other Party for its reasonable costs so incurred. The decision of such independent laboratory shall be in writing and shall be
binding on both Parties unless there has been a manifest error on the face of the decision whereupon the Parties shall revert to the arbitration procedure set forth in Section 14. For the avoidance of doubt, the Parties will follow Diosynth
quality procedures while accepting or rejecting the disputed Batch.  

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	7

	 	h)	The Parties hereby agree following the production of a certain number of Batches to be determined in good faith by the Parties, to discuss in good faith an amendment to
the definition of Diosynth Factor to account for Diosynth’s increased level of understanding with respect to the manufacturing process necessary to produce such Batches. 

 Section 6. 
 Change Orders 

 

	 	a)	The total budget for the Program specified in the Program Price and Payment Schedule, the individual budget components and the estimated durations specified in the
Scope are subject to the Assumptions (as defined below) as well as the accuracy, timeliness and completeness of Sponsor’s Deliverables. Such Assumptions relate to the Program design and objectives, manpower requirements, timing, capital
expenditure requirements, if any and other matters relating to the completion of the Program and are set forth in the Scope (“Program Assumptions”). Diosynth also assumes that Sponsor will cooperate and perform its obligations under
this Agreement and the Scope in a timely manner, that no Force Majeure event will occur, and that there are no changes to any applicable laws, rules or regulations which materially affect the performance of the Program (the foregoing assumptions,
together with the Program Assumptions, collectively, the “Assumptions”). In the event that any of the Assumptions require modification to this Agreement or the Program objectives cannot reasonably be achieved as a result of one or
more of the Assumptions being materially incorrect (each being a “Modification”), the Scope may be amended as provided in paragraph b) of this Section 6. 

 

	 	b)	In the event a Modification is identified by Sponsor or by Diosynth, the identifying Party shall notify the other Party in writing as soon as is reasonably possible.
Diosynth shall provide Sponsor with a change order containing an estimate of the additional cost to Sponsor of such Modifications including any changes that may be necessary to the Program budget, activities and/or estimated duration as specified in
the Scope (“Change Order”) within ten (10) business days of receiving such notice or providing such notice to Sponsor. Sponsor shall respond in writing to such Change Order within ten (10) business days of receiving such
Change Order indicating whether or not it approves the proposed Change Order. Sponsor shall be deemed to have not approved the Change Order if Diosynth does not receive a written indication from Sponsor during such ten (10) day period. If
Sponsor does not approve such Change Order, then Sponsor and Diosynth shall negotiate in good faith to agree on a Change Order that is mutually acceptable. If practicable, Diosynth shall continue work on the Program during any such negotiations, but
shall not commence work with respect to the Change Order unless authorized in writing by Sponsor. If the Parties are unable to agree upon a Change Order within forty-five (45) days after issuance of the relevant Change Order, then Diosynth
shall, if reasonably possible, perform the Scope without regard to the unresolved Change Order; provided, however, that the estimated timelines shall be adjusted to reflect any delay during the negotiation period. In the event that in
Diosynth’s reasonable judgment such performance in not possible in accordance with the current Scope and Program Price and Payment Schedule, then Diosynth shall provide written notice to Sponsor of its inability to perform in the absence of an
agreed upon Change Order (the “Impasse Notice”). Upon issuance of an Impasse Notice, either Party shall have the right to terminate this Agreement or the Program affected by such Change Order within thirty (30) days following
the date of delivery of such Impasse Notice. 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	8

 Section 7. 
 Confidential Information/Legal Proceedings 
  

	 	a)	During the Term of this Agreement and for five (5) years following the termination of this Agreement, Diosynth will hold in confidence and will not disclose,
without Sponsor’s prior written permission, any Confidential Information pertaining to the Program or otherwise disclosed by Sponsor to Diosynth in connection with the Program (“Sponsor Confidential Information”) unless:
(i) such disclosure is to an affiliate of Diosynth that is under an obligation to keep such information confidential comparable in scope to Diosynth’s obligation under this Section 7; (ii) such information is or becomes publicly
available through no fault of Diosynth; (iii) such information is disclosed to Diosynth by a third party entitled to disclose it; (iv) such information is already known to Diosynth as shown by its prior written records; or, (v) such
information is required by any law, rule, regulation, order decision, decree, subpoena or other legal process to be disclosed. If such disclosure is requested by legal process, Diosynth will use reasonable efforts to notify Sponsor of this request
promptly prior to any disclosure to permit Sponsor to oppose such disclosure by appropriate legal action. Diosynth shall use reasonable precautions to protect the confidentiality of Sponsor Confidential Information comparable to precautions taken to
protect its own proprietary information. 

  

	 	b)	During the Term of this Agreement and for five (5) years following the termination of this Agreement, Sponsor will hold in confidence and not disclose, without
Diosynth’s prior written permission, any Confidential Information pertaining to Diosynth’s performance of the Program disclosed by Diosynth to Sponsor (“Diosynth Confidential Information”) unless: (i) such disclosure
is to an affiliate of Sponsor that is under a similar obligation to keep such information confidential; (ii) such information is or becomes publicly available through no fault of Sponsor; (iii) such information is disclosed by a third
party entitled to disclose it; (iv) such information is already known to Sponsor as shown by its prior written records; or, (v) such information is required by any law, rule, regulation, order decision, decree, subpoena or other legal
process to be disclosed. If such disclosure is requested by legal process, Sponsor will use reasonable efforts to notify Diosynth of this request promptly prior to any disclosure to permit Diosynth to oppose such disclosure by appropriate legal
action. Sponsor shall use reasonable precautions to protect the confidentiality of Diosynth Confidential Information comparable to precautions taken to protect its own proprietary information. 

 

	 	c)	If either Party shall be obliged to provide testimony or records with respect to the Confidential Information of the other in any legal or administrative proceeding,
then the Party to whom the Confidential Information belongs shall reimburse the other Party for its out-of-pocket costs incurred in providing such testimony or records plus an hourly fee for its employees or representatives used to provide such
testimony or records, which shall be based on the internal fully burdened costs of such employee or representative. 

  

	 	d)	For both Parties, “Confidential Information” shall mean and include without limitation inventions, methods, plans, processes, specifications,
characteristics, raw data, analyses, equipment design, trade secrets, costs, marketing, sales, and performance information, including patents and patent applications, grant applications, notes, and memoranda, whether in writing or presented, stored
or maintained electronically, magnetically or by other means, which are disclosed by the disclosing Party to the recipient Party in writing or in other tangible form and whether or not marked “confidential”; provided, that, if disclosed
orally (or in some other non-tangible form), the disclosing Party shall use reasonable efforts to identify such information as confidential to the recipient Party in writing within sixty (60) days of such oral disclosure.

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	9

	 	e)	Upon the expiration or termination of this Agreement, to the extent requested by the disclosing Party, each recipient Party shall use all reasonable efforts to collect
and return to the disclosing Party any and all data, notes, records, reports, and other electronic or written information, including any and all copies that may have been made thereof, that contain Confidential Information received from the
disclosing Party; provided, that, each recipient Party shall be entitled to keep one archival copy of Confidential Information provided by the disclosing Party in its confidential files. 

Section 8. 
 Work Output

  

	 	a)	All Information, data, documentation and reports produced by Diosynth in the conduct of the Program and/or all other cGMP documentation (“Work Output”)
will be prepared by Diosynth using Diosynth’s standard format(s) unless otherwise specified in the Scope. 

  

	 	b)	Sponsor will be supplied with copies of Work Output generated as a result of the Program as set forth in the Scope or Quality Agreement. Notwithstanding the foregoing,
Diosynth shall not be obliged to supply all data generated but instead will supply relevant data to Sponsor and Sponsor will have access to all data generated in relation to the Program for on-site review either (i) during any audits or
(ii) upon Sponsor’s written request. All Work Output and Product samples will be archived by Diosynth for a period of five (5) years following completion of the Program unless otherwise defined by the Program or required by applicable
U.S. laws or regulations. Five (5) years after completion of the Program, Work Output and Product samples will be disposed by Diosynth or sent by Diosynth to Sponsor and a return fee will be charged, as specified in writing by Sponsor. Sponsor
may elect to have the Work Output retained in the Diosynth archives for an additional period of time at additional cost to Sponsor. If Sponsor chooses to have Diosynth dispose of Work Output and Product samples, a disposal fee will be charged.
Notwithstanding the foregoing, Diosynth will continue to retain such Work Output and Product samples as required by regulations and as may be required by law, pertaining to such activities as well as for archival purposes. In the absence of notice
at the end of the applicable period, Diosynth shall send the Work Product to Sponsor at Sponsor’s cost and expense. 

Section 9. 
 Inventions and Patents

  

	 	a)	Diosynth shall promptly and fully disclose to Sponsor any and all inventions, improvements, developments, original works of authorship or other intellectual property
conceived, developed and/or reduced to practice, whether in whole or in part, by Diosynth in the course of the performance of the Program (collectively, “Program Inventions”). 

 

	 	b)	 All Program Inventions that relate to Diosynth’s general manufacturing and analytical methods and that are not specific to the Product or Sponsor
Deliverables shall be Confidential Information of, and shall be solely owned by, Diosynth (collectively, “Process Inventions”). All other Program Inventions, including without limitation, any Program Inventions that are specific to
the Product or the Sponsor Deliverables (collectively, “Product Inventions”) shall be Confidential Information of, and shall be solely owned by, Sponsor. Diosynth hereby agrees to assign, and does hereby assign, to Sponsor and its
successors and assigns, without further consideration, its entire right, title and interest in any Product Inventions, whether or not patentable. If Sponsor requests and at Sponsor’s expense, Diosynth will execute any and all applications,
assignments or other instruments 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	10

	 	
and give testimony which shall be necessary to apply for and obtain Letters of Patent of the US or of any foreign country with respect to any Product Inventions and Sponsor shall compensate
Diosynth for the time devoted to such activities and reimburse it for expenses incurred. For Product Inventions assigned pursuant to this section, Sponsor shall provide Diosynth a royalty-free license necessary to perform the Program for the Term of
this Agreement.  

 Diosynth agrees to grant and hereby grants to Sponsor a perpetual, world-wide,
royalty-free, sublicensable, exclusive license under all Process Inventions for use in connection with the Product. If Diosynth requests and at Diosynth’s expense, Sponsor will execute any and all applications, assignments or other instruments
and give testimony which shall be necessary to apply for and obtain Letters of Patent of the US or of any foreign country with respect to any Process Inventions and Diosynth shall compensate Sponsor for the time devoted to such activities and
reimburse it for expenses incurred. 
  

	 	c)	Diosynth reserves the right to use data during the course of the Program to support applications, assignments or other instruments necessary to apply for and obtain
Letters of Patent of the U.S. or any foreign country with respect to Process Inventions so long as no information which Diosynth is required to keep confidential under this Agreement is disclosed in any such application, assignment, or other
instrument. Diosynth shall notify Sponsor ninety (90) days in advance of intent to file such application, assignment or other instrument and Sponsor shall have the right to request that any Sponsor Confidential Information contained in any such
application, assignment or other instrument be deleted therefrom. 

 Section 10. 

Independent Contractor 
 Diosynth
shall perform the Program as an independent contractor of Sponsor and shall have complete and exclusive control over its facilities, equipment, employees and agents. The provisions of this Agreement shall not be construed to establish any form of
partnership, agency or other joint venture of any kind between Diosynth and Sponsor, nor to constitute either Party as the agent, employee or legal representative of the other. All persons furnished by either Party to accomplish the intent of this
Agreement shall be considered solely as the furnishing Party’s employees or agents and the furnishing Party shall be solely responsible for compliance with all laws, rules and regulations involving, but not limited to, employment of labor,
hours of labor, working conditions, workers’ compensation, payment of wages, and withholding and payment of applicable taxes, including, but not limited to income taxes, unemployment taxes, and social security taxes. 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	11

 Section 11. 
 Insurance 
  

	 	a)	Diosynth shall secure and maintain in full force and effect throughout the performance of the Program policies of insurance with companies with an AM Best Rating of at
least A-, VII or its equivalent for (a) workmen’s compensation with statutory limits, (b) general liability with combined single limits of not less than $5,000,000 per occurrence and $5,000,000 in the aggregate, (c) product
liability with combined single limits of not less than $5,000,000 per occurrence and $5,000,000 in the aggregate and (d) property damage (including business interruption coverage) with limits equal to replacement value, and, in each case,
having deductibles and other terms appropriate to the conduct of Diosynth’s business in Diosynth’s reasonable judgment.  

  

	 	b)	Sponsor shall secure and maintain in full force and effect throughout the performance of the Program policies of insurance for (a) general liability and
(b) product liability having policy limits, deductibles and other terms appropriate to the conduct of Sponsor’s business in Sponsor’s reasonable judgment. 

 Section 12. 
 Delivery 
 Diosynth shall package for shipment and deliver Product, samples or other materials at Sponsor’s expense and in accordance with Sponsor’s full written and reasonable instructions with Sponsor
bearing all packaging, shipping and insurance charges. Freight terms shall be Ex Works (Incoterms 2010) the GMP Facility. Title, possession, risk of loss, risk of damage and all forward costs and expenses shall pass to and be borne by Sponsor upon
delivery. Diosynth shall retain representative samples of Product for record keeping, testing and regulatory purposes. Sponsor shall provide for shipping of each Batch of Product within thirty (30) calendar days of its issuance of certificate
of compliance in accordance with Section 5(f), unless otherwise agreed between the Parties. In the event of any delay by Sponsor in issuance of the certificate of compliance or shipping of Product in accordance with this Section 12, the
Parties acknowledge and agree that liability and risk of loss for each such shipment of Product shall automatically transfer to (and be assumed by) Sponsor effective upon expiration of sixty (60) days period since completion of manufacturing.

 Section 13. 

Default/Limitation of Warranty 
  

	 	a)	If Diosynth is in default of its material obligations under this Agreement, Sponsor shall promptly notify Diosynth in writing of any such default. Diosynth shall have a
period of forty-five (45) days from the date of receipt of such notice within which to cure or, if a cure cannot reasonably be effected within such forty-five (45) day period, to deliver to Sponsor a plan for curing such breach that is
reasonably sufficient to effect a cure as soon as practicable thereafter and to commence in good faith to cure such default in accordance with the plan within such forty-five (45) day period; provided, that, if the cure involves the supply to
Sponsor of a replacement shipment of Product, the Parties will agree in good faith on a reasonable date by which Diosynth shall supply such Product. If Diosynth fails to so cure, or commence to cure, such breach, then this Agreement shall, at
Sponsor’s option, immediately terminate. 

  

	 	b)	 If Sponsor is in default of its material obligations under this Agreement, Diosynth shall promptly notify Sponsor in writing of any such default.
Sponsor shall have a period of forty-five (45) days from the date of receipt of such notice within which to cure such default 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	12

	 	
or, if a cure cannot reasonably be effected within such forty-five (45) day period, to deliver to Diosynth a plan for curing such breach that is reasonably sufficient to effect a cure as
soon as practicable thereafter and to commence in good faith to cure such default in accordance with the plan within such forty-five (45) day period. If Sponsor fails to so cure, or commence to cure, such breach within the specified cure
period, this Agreement may, at Diosynth’s option, immediately terminate. 

  

	 	c)	Not withstanding anything herein to the contrary, EXCEPT AS SET FORTH IN SECTION 15, UNDER NO CIRCUMSTANCES SHALL EITHER PARTY BE ENTITLED TO INCIDENTAL, INDIRECT,
CONSEQUENTIAL OR SPECIAL DAMAGES ARISING IN CONNECTION WITH THE DEFAULT OR BREACH OF ANY OBLIGATION OF THE OTHER PARTY UNDER THIS AGREEMENT, THE SCOPE OR ANY DOCUMENTS OR APPENDICES RELATED THERETO. EXCEPT FOR THE OBLIGATIONS OF DIOSYNTH UNDER
SECTION 15(a), THE MAXIMUM LIABILITY OF DIOSYNTH FOR DAMAGES IN CONNECTION WITH A CLAIM RELATED TO THIS AGREEMENT, REGARDLESS OF THE CAUSE OF ACTION, [*]. 

 

	 	d)	EXCEPT AS EXPRESSLY STATED HEREIN, NEITHER PARTY PROVIDES TO THE OTHER PARTY HERETO ANY WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE MATERIALS AND SERVICES
PROVIDED HEREUNDER, AND ALL SUCH WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE ARE WAIVED. SUBJECT TO DIOSYNTH’S OBLIGATIONS WITH RESPECT TO THE
QUALITY OF THEIR SERVICES AS DESCRIBED HEREIN, INCLUDING THE APPLICABLE SCOPE OF WORK, QUALITY AGREEMENT OR OTHER AGREEMENT BETWEEN THE PARTIES, DIOSYNTH MAKES NO WARRANTIES THAT THE EXECUTION OF THE SCOPE WILL RESULT IN ANY SPECIFIC QUANTITY OR
QUALITY OF PRODUCT. 

 Section 14. 
 Dispute Resolution 
  

	 	a)	In the event any dispute shall arise between Sponsor and Diosynth with respect to any of the terms and conditions of this Agreement or the Program the senior executives
of Sponsor and Diosynth shall meet as promptly as practicable after notice of such dispute to resolve in good faith such dispute. 

  

	 	b)	If Sponsor and Diosynth are unable to satisfactorily resolve the dispute within thirty (30) days following referral to the senior executives, then such dispute
shall be referred to mediation in accordance with the rules of the American Arbitration Association. The Parties shall participate in the mediation in a good faith attempt to settle the dispute. The mediation shall be held in Washington, D.C.

  

	 	c)	 If mediation fails to resolve the dispute within forty-five (45) days of the initial meeting pursuant to Section 14 a) above, then such
dispute shall be finally settled by an arbitrator in accordance with this Section 14. The arbitration will be held in Washington, D.C., and except as noted below, shall be conducted in accordance with the rules of the American Arbitration
Association by a neutral arbitrator agreeable to both Parties. If the Parties do not agree on an arbitrator within thirty (30) days of the termination of the mediation as indicated by at least one of the Parties, the American Arbitration
Association shall appoint an arbitrator to hear the case in accordance with its rules. The arbitrator shall have no 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	13

	 	
authority to award consequential, punitive or exemplary damages or to vary from or ignore the terms of this Agreement and shall be bound by controlling law. The Parties may seek judicial
intervention for emergency relief, such as restraining orders and injunctions where appropriate. 

  

	 	d)	Any decision by the arbitrator shall be binding upon the Parties and may be entered as final judgment in any court having jurisdiction. The cost of any arbitration
proceeding shall be borne by the Parties as the arbitrator shall determine if the Parties have not otherwise agreed. The arbitrator shall render a final decision in writing to the Parties. 

Section 15. 
 Indemnification

  

	 	a)	Diosynth shall indemnify Sponsor and its affiliates and their respective officers, directors and employees (“Sponsor Indemnitees”) from any loss, cost,
damage or expense (“Loss”) from any lawsuit, action, claim, demand, assessment or proceeding made or brought by a third party (“Claim”) arising from or related to (i) the material breach of any representation
or warranty by Diosynth under this Agreement; (ii) the failure of Diosynth to perform the Services in accordance with the Scope; (iii) the material breach by Diosynth of any applicable statute or regulation relating to the Program; or
(iv) Diosynth’s negligence or intentional misconduct or inaction (including violation or non-performance of this Agreement); provided, that, if such Loss or Claim arises in whole or in part from Sponsor’s negligence or intentional
misconduct or inaction, then the amount of the Loss that Diosynth shall indemnify Sponsor Indemnitees for pursuant to this Section 15 shall be reduced by an amount in proportion to the percentage of Sponsor’s responsibilities for such Loss
determined by a court of competent jurisdiction in a final and non-appealable decision or in a binding settlement between the Parties. 

  

	 	b)	Sponsor shall indemnify Diosynth and its affiliates and their respective officers, directors and employees (“Diosynth Indemnitees”) from any Claim or
Loss arising from or related to: (i) the use by Sponsor of Sponsor Deliverables, Process Consumables, or the Product; (ii) the material breach of any representation or warranty by Sponsor under this Agreement; (iii) the infringement
or alleged infringement of the intellectual property rights of a third party arising out of Diosynth’s use of any technical information, materials or know-how provided by Sponsor to Diosynth for Diosynth’s conduct of the Program in
accordance with the Scope; or (iv) the negligence or intentional misconduct or inaction of Sponsor; provided, that, if such Loss or Claim arises in whole or in part from Diosynth’s negligence, gross negligence or intentional misconduct or
inaction, then the amount of such Loss that Sponsor shall indemnify the Diosynth Indemnitees for pursuant to this Section 15 shall be reduced by an amount in proportion to the percentage of Diosynth’s responsibilities for such Loss as
determined by a court of competent jurisdiction in a final and non-appealable decision or in a binding settlement between the Parties. 

  

	 	c)	 Upon receipt of notice of any Claim which may give rise to a right of indemnity from the other Party hereto, the Party seeking indemnification (the
“Indemnified Party”) shall give written notice thereof to the other Party, (the “Indemnifying Party”) with a Claim for indemnity (“Indemnity Claim”). Any delay or failure to give notice shall not
discharge the duty of the Indemnifying Party to indemnify except to the extent it is prejudiced by such delay or failure. Such Indemnity Claim shall indicate the nature of the Indemnity Claim and the basis therefore. Promptly after an Indemnity
Claim is made for which the Indemnified Party seeks indemnity, the Indemnified Party shall permit the Indemnifying Party, at its option and expense, to assume the complete defense of such Indemnity

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	14

	 	
Claim; provided, that, (i) the Indemnified Party will have the right to participate in the defense of any such Indemnity Claim at its own cost and expense, (ii) the Indemnifying Party
will conduct the defense of any such Indemnity Claim with due regard for the business interests and potential related liabilities of the Indemnified Party and (iii) the Indemnifying Party will, prior to making any settlement, consult with the
Indemnified Party as to the terms of such settlement and receive approval thereof, not to be unreasonably withheld. The Indemnified Party shall have the right, at its election, to release and hold harmless the Indemnifying Party from its obligations
hereunder with respect to such Indemnity Claim and assume the complete defense of the same in return for payment by the Indemnifying Party to the Indemnified Party of the amount of the Indemnifying Party’s settlement offer. The Indemnifying
Party will not, in defense of any such Indemnity Claim, except with the consent of the Indemnified Party, consent to the entry of any judgment or enter into any settlement which does not include as an unconditional term thereof, the giving by the
claimant or plaintiff to the Indemnified Party of a release from all liability in respect thereof. After notice to the Indemnified Party of the Indemnifying Party’s election to assume the defense of such Indemnity Claim, the Indemnifying Party
shall be liable to the Indemnified Party for such legal or other expenses subsequently incurred by the Indemnified Party in connection with the defense thereof at the request of the Indemnifying Party. As to those Indemnity Claims with respect to
which the Indemnifying Party does not elect to assume control of the defense, the Indemnified Party will afford the Indemnifying Party an opportunity to participate in such defense at the Indemnifying Party’s own cost and expense, and will not
settle or otherwise dispose of any of the same without the consent of the Indemnifying Party. 

 Section 16. 

Representations and Warranties 
  

	 	a)	Each Party represents and warrants to the other that it has the full right and authority to enter into this Agreement and to perform this Agreement in accordance with
the terms and conditions set forth herein; this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, binding obligation, enforceable against such Party in accordance with its terms except as
enforceability may be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating to or affecting creditors’ rights generally and by general equitable principles; the execution, delivery and
performance of this Agreement does not breach, violate, contravene or constitute a default under any contract or commitment to which such Party is a party or by which it is bound nor does the execution, delivery and performance of this Agreement by
such Party violate any order, law or regulation of any court, governmental body or administrative or other agency having authority over it. Each Party represents and warrants to the other that neither it nor any of its officers, directors, or its
employees performing services under this Agreement has been debarred, or convicted of a crime which could lead to debarment, under the Generic Drug Enforcement Act of 1992, 21 United States Code §§335(a) and (b). 

 

	 	b)	Each Party represents and warrants to the other Party that it has obtained and will at all times during the term of this Agreement, hold and comply with all licenses,
permits and authorizations necessary to perform this Agreement as now or hereafter required under any applicable statutes, laws, ordinances, rules and regulations of the United States and any applicable foreign, state, and local governments and
governmental entities. 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	15

	 	c)	Sponsor hereby represents and warrants to Diosynth that it has legal title and/or a valid license to the Sponsor Deliverables necessary to conduct the Program in
accordance with the Scope. 

  

	 	d)	Diosynth hereby represents and warrants to Sponsor that (i) Diosynth will operate the GMP Facility in compliance with cGMP in all aspects of manufacturing,
testing, holding, packaging, labeling and preparation for shipping of the Product and will perform the Program in compliance with cGMP and that the Products will conform to the packaging instructions provided by Sponsor and agreed upon by
Diosynth; (ii) Diosynth owns or lawfully controls the GMP Facility, and the GMP Facility shall be maintained in accordance with cGMP and in such condition as will allow Diosynth to manufacture the Product in compliance with cGMP;
(iii) Diosynth has written agreements with all its employees involved in the performance of the Services, which agreements shall require that all discoveries and inventions conceived or reduced to practice by such employees in the conduct of
the Services shall be promptly disclosed and assigned to Diosynth; and Diosynth has the right to assign to Sponsor its rights in and to all Product Inventions as provided in this Agreement; (iv) Diosynth is under no contractual or other
obligation or restriction that is inconsistent with Diosynth’s performance of this Agreement; and (v) in performing this Agreement, Diosynth will comply with all applicable laws and perform the Program in compliance with applicable cGMP
regulations, except as specified otherwise in this Agreement. 

 Section 17. 

Force Majeure 
 Either Party shall
be excused from performing its respective obligations under this Agreement if its performance is delayed or prevented by any event beyond such Party’s reasonable control, including, but not limited to, acts of God, fire, explosion, weather,
disease, war, insurrection, civil strife, riots, government action, acts of terrorism or power failure; provided, that, such performance shall be excused only to the extent of and during such disability. The Party subject to such event shall
promptly notify the other Party of the occurrence thereof and, if known, the expected duration. Any time specified or estimated for completion of performance in the Scope falling due during or subsequent to the occurrence of any or such events shall
be automatically extended for a period of time to recover from such disability. Diosynth will promptly notify Sponsor if, by reason of any of the events referred to herein, Diosynth is unable to meet any such time for performance specified or
estimated in the Scope. If any part of the Program is invalid as a result of such disability, Diosynth will, upon written request from Sponsor, but at Sponsor’s sole cost and expense, repeat that part of the Program affected by the disability.

 Section 18. 
 Allocation
of Resources 
 If delays in the agreed commencement or performance of the Program occur because of Sponsor’s request or inability
to supply Diosynth with agreed Sponsor Deliverables or any information required to begin or perform the Program within thirty (30) days of such agreed time, Diosynth may reallocate resources being held for performance of the Program. In such
event, Diosynth shall be relieved of its obligation to perform the Program as set forth in the Scope except that upon such delay being removed or remedied, Diosynth will use commercially reasonable efforts to allocate resources to performance of the
Program as set forth in the Scope. 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	16

 Section 19. 
 Use of Names 
 The Parties anticipate opportunities for joint or independent press
releases or other announcements relating to the activities contemplated hereby. Notwithstanding the foregoing, neither Party shall use the name of the other Party or the names of the employees of the other Party in any advertising or sales
promotional material or in any publication without prior written permission of such Party. Such consent may not be unreasonably withheld. This provision shall not restrict a Party’s ability to use the other Party’s name and to disclose the
terms of this Agreement to the extent required by law or by the requirements of any nationally recognized securities exchange, quotation system or over-the-counter market on which such Party has its securities listed or traded. In the event that
such disclosure is required as aforesaid, the disclosing Party shall make reasonable efforts to provide the other Party with notice beforehand and to coordinate with the other Party with respect to the wording and timing of any such disclosure.

 Section 20. 

Term/Termination 
  

	 	a)	This Agreement shall take effect on the date first written above and continue in effect, unless earlier terminated pursuant to this Section 20, until the
completion of the Program (the “Term”). 

  

	 	b)	In addition to the termination rights set forth in Section 13, Sponsor may at any time terminate this Agreement by giving forty-five (45) days written notice
to Diosynth. In the event Sponsor elects to terminate for reasons other than pursuant to Section 13 or in the event that Diosynth terminates this Agreement pursuant to Section 13, then, as Diosynth’s sole remedy under this Agreement,
Sponsor shall pay Diosynth upon receipt of Diosynth’s invoice, the following amounts: 

  

	 	(i)	All amounts owed for services completed but not yet invoiced; plus 

  

	 	(ii)	All unpaid costs incurred or committed for Process Consumables; plus 

  

	 	(iii)	A termination fee to be paid on or before forty-five (45) days of the effective date of termination, calculated as follows: 

(A) [*] of any unbilled amounts set forth in the Program Price and Payment Schedule under all headings, other than
“Manufacturing”; plus 
 (B) (1) If the effective date of termination is within [*] of the scheduled commencement
date for manufacturing activities, but prior to the date that is [*] prior to the scheduled commencement for manufacturing activities, an amount equal to [*] of the unbilled activities under the Manufacturing heading in the Program Price and Payment
Schedule (as amended to include any executed Change Orders); or 
 (B) (2) If the effective date of termination is within
[*] of the scheduled commencement date for manufacturing activities, but prior to the date that is [*] prior to the scheduled commencement for manufacturing activities, an amount equal to [*] of the unbilled activities under the Manufacturing
heading in the Program Price and Payment Schedule (as amended to include any executed Change Orders); or 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	17

 (B) (3) If the effective date of termination is within [*] of the scheduled
commencement date for manufacturing activities, but prior to the date that is [*] prior to the scheduled commencement for manufacturing activities, an amount equal to [*] of the unbilled activities under the Manufacturing heading in the Program
Price and Payment Schedule (as amended to include any executed Change Orders); or 
 (B) (4) If the effective date of
termination is within [*] of the scheduled commencement date for manufacturing activities, an amount equal to [*] of the unbilled activities under the Manufacturing heading in the Program Price and Payment Schedule (as amended to include any
executed Change Orders). 
  

	 	c)	For the avoidance of doubt, the provisions of this Section 20 shall not apply to delays, including without limitation, Sponsor Delays, which are addressed in
Section 5(c). For the avoidance of doubt, in the event of termination of this Agreement for any reason, (i) Diosynth will terminate all services in progress under the Program in an orderly manner as soon as practical and in accordance with
a schedule agreed to by Sponsor, unless Sponsor specifies in the notice of termination that such services in progress should be completed, (ii) Diosynth will deliver to Sponsor any Sponsor Deliverables and Work Output in its possession or
control and all Product Inventions developed through the date of termination or expiration, and (iii) Sponsor will pay Diosynth any monies due and owing Diosynth, up to the time of termination or expiration, for services actually performed and
all authorized expenses actually incurred pursuant to Section 20(b). The termination of this Agreement for any reason shall relieve neither Party of its obligation to the other for obligations in respect of: (i) confidentiality of
information; (ii) consents for advertising purposes and publications; (iii) indemnification; (iv) inventions and patents; (v) compensation for services performed and (vi) dispute resolution. 

Section 21. 
 Program
Management. 
 a) Joint Steering Committee. Effective on the Effective Date, Sponsor and Diosynth shall
establish a Joint Steering Committee (the “Joint Steering Committee”) comprised of an equal number of representatives designated by Sponsor and Diosynth. 

 

	 	b)	Alliance Managers. Each Party shall appoint one person to serve as an Alliance Manager (each, an “Alliance Manager”) with responsibility for
overseeing the day-to-day activities of the Parties with respect to the Program and for being the primary point of contact between the Parties with respect to the Program. The Diosynth customer Project Leader will serve as the Diosynth Alliance
Manager. The Alliance Managers shall report to the Joint Steering Committee. 

  

	 	c)	Replacement of Joint Steering Committee Representatives and Alliance Managers. Each Party shall be free to replace its representative members on the Joint
Steering Committee or its Alliance Manager with new appointees who have authority to act on behalf of such Party, on notice to the other Party. 

  

	 	d)	Responsibilities of Joint Steering Committee. The Joint Steering Committee shall be responsible for overseeing and directing the Parties’ interaction and
performance of their respective obligations under this Agreement. Without limiting the generality of the foregoing, its duties shall include: 

  

	 	(i)	monitoring the performance of the Program; 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	18

	 	(ii)	resolving disagreements that arise under the Agreement; and 

  

	 	(iii)	determining the need for and terms of any Change Orders. 

  

	 	e)	Meetings. The Joint Steering Committee shall meet at such times as the Joint Steering Committee determines to resolve issues arising hereunder and to perform its
responsibilities under this Agreement; provided, that, the Joint Steering Committee shall meet not less than four (4) times per calendar year unless otherwise mutually agreed. Such meetings may be in person or by telephone as agreed by the
Joint Steering Committee. To the extent that meetings are held in person, they shall alternate between the offices of the Parties unless the Parties agree otherwise. The Alliance Managers shall attend all meetings of the Joint Steering Committee.
All decisions of the Joint Steering Committee shall be unanimous. The first meeting shall be held on or before January     , 2013. 

  

	 	f)	Administration. The chairperson of the Joint Steering Committee shall be designated every six (6) months on an alternating basis between the Parties. The
initial chairperson will be selected by Diosynth. The chairperson shall be responsible for calling meetings, sending notices of meetings and for leading such meetings. 

 

	 	g)	Minutes. Within fifteen (15) days after each Joint Steering Committee meeting, the Alliance Manager for the party whose representative chaired the Joint
Steering Committee meeting shall prepare and distribute minutes of the meeting, which shall provide a description in reasonable detail of the discussions had at the meeting and a list of any actions, decisions or determinations approved by the Joint
Steering Committee. Minutes shall be approved or disapproved and revised, as necessary, at the next meeting. Final minutes shall be distributed to the members of the Joint Steering Committee. 

 

	 	h)	Dispute Resolution. In the event that the Joint Steering Committee cannot reach agreement with respect to any material issue, then the issue shall be resolved in
accordance with the dispute resolution provisions in Section 14. 

  

	 	i)	Limitations. The Joint Steering Committee is not empowered to amend the terms of this Agreement. 

Section 22. 
 Assignment

 This Agreement shall not be assigned in whole or in part by either Party without the prior written consent of the other, which consent
shall not be unreasonably withheld or delayed. Any attempt to assign this Agreement without such consent shall be void and of no effect. Notwithstanding the foregoing, either Party shall be entitled, without the prior written consent of the other
Party, to assign all or any part of its rights under this Agreement to a purchaser of all or substantially all of its assets to which this Agreement relates, or an entity with which it may merge or sell its capital stock where it is not the
surviving company; provided, that, the assignee agrees in writing to assume all obligations undertaken by its assignor in this Agreement. No assignment shall relieve the assigning Party of responsibility for the performance of any of its obligations
hereunder. The terms of this Agreement shall inure to the benefit of successors and assigns. 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	19

 Section 23. 
 Notice 
 All notices to be given as required in this Agreement shall be in writing
and shall be delivered personally, sent by telecopies, or mailed either by a reputable overnight carrier or first class mail, postage prepaid to the Parties at the addresses set forth below or such other addresses as the Parties may designate in
writing. Such notice shall be effective on the date sent, if delivered personally or sent by telecopier, the date after delivery if sent by overnight carrier and on the date received if mailed first class. 

If to Sponsor: 
 Synageva BioPharma
Corp. 
 128 Spring Street, Suite 520 

Lexington, MA 02421 
 P: 781-357-9900 

F: 781-357-9901 
 Attention: Legal Department

 If to Diosynth: 
 President

 Fujifilm Diosynth Biotechnologies 

101 J. Morris Commons Lane 
 Morrisville, NC
27560 
 P: 919-337-4404 
 F:
919-337-0899 
 With copies to: 

General Counsel 
 Fujifilm Diosynth
Biotechnologies 
 Hexagon Tower 

Blackley, Manchester, M9 8ES, United Kingdom 

Facsimile No.: +44 161 721 5801 
 Assistant
General Counsel 
 FUJIFILM Holdings America Corporation 
 200 Summit Lake Drive 
 Valhalla, New York 10595-1356 

Fax: 914-789-8514 
 Section 24. 

Choice of Law 
 This Agreement
shall be construed and enforced in accordance with the laws of and in the venue of the State of Delaware except for its rules regarding conflict of laws. 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	20

 Section 25. 
 Waiver/Severability 
 No waiver of any provision of this Agreement, whether by
conduct or otherwise, in any one or more instances shall be deemed to be or be construed as a further or continuing waiver of any such provision, or of any other provision or condition of this Agreement. If any provisions hereof shall be determined
to be invalid or unenforceable, the validity and effect of the other provisions of this Agreement shall not be affected thereby. 

Section 26. 
 Nonsolicitation

 For the term of this Agreement, and for twelve (12) months following termination of this Agreement, for any reason, neither
Sponsor nor Diosynth nor any of their employees or agents shall, directly or indirectly, solicit, hire, or attempt to solicit or hire, any employees of the other who were involved in the Program, unless otherwise approved by the other Party. This
provision shall not restrict either Party or its affiliates from advertising employment opportunities in any manner that does not directly target the other Party or its Affiliates. 
 Section 27. 
 Entire Agreement; Modification/Counterparts 

 

	 	a)	This instrument including the attached Appendices sets forth the entire agreement between the Parties hereto with respect to the performance of the Program by Diosynth
for Sponsor and as such, supersedes all prior and contemporaneous negotiations, agreements, representations, understandings, and commitments with respect thereto and shall take precedence over all terms, conditions and provisions on any purchase
order form or form of order acknowledgment or other document purporting to address the same subject matter. This Agreement shall not be waived, released, discharged, changed or modified in any manner except by an instrument signed by the duly
authorized officers of each of the Parties hereto, which instrument shall make specific reference to this Agreement and shall express the plan or intention to modify same. 

 

	 	b)	This Agreement may be executed in one or more counterparts each of which shall be deemed an original but all of which together shall constitute one and the same
instrument. 

  

	 	c)	This Agreement becomes effective and binding on both Parties on and as of the last date that the Parties hereto have executed this Agreement. Should terms contained
herein be at variance with the terms and conditions specified in Sponsor’s written acceptance, then the terms and conditions contained herein take precedence. 

[Remainder of page intentionally left blank.] 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	21

									
	Synageva BioPharma Corp.	 		 	FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
					
	By:	 	 /s/ Stephen Mahoney
	 		 	By:	 	 /s/ Henrik Edeback

					
	Name:	 	 Stephen Mahoney
	 		 	Name:	 	 Henrik Edeback

					
	Title:	 	 VP, General Counsel
	 		 	Title:	 	 VP Finance

					
	Date:	 	 1/22/13
	 		 	Date:	 	 1/22/13

				
		 		 		 	FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
					
		 		 		 	By:	 	 /s/ Stephen Spearman

					
		 		 		 	Name:	 	 Stephen Spearman

					
		 		 		 	Title:	 	 President

					
		 		 		 	Date:	 	 22 Jan 2013

 [Signature page to Bioprocessing Services Agreement] 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	22

 SOW Technology Transfer and Manufacture of SBC-102 

APPENDIX 1 
  

 
 Scope of Work for Technology
Transfer 
 and cGMP Manufacture of SBC-102 
 Drug Substance 
  

 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	Page 1 of 20

 SOW Technology Transfer and Manufacture of SBC-102 
  
 TABLE OF CONTENTS 
  

							
			
	 1.0
	 	 PROGRAM DEFINITIONS
	  	 	3	  
			
	 2.0
	 	 ACRONYMS
	  	 	5	  
			
	 3.0
	 	 INTRODUCTION
	  	 	6	  
			
	 4.0
	 	 SCOPE ASSUMPTIONS
	  	 	7	  
			
	 5.0
	 	 SPONSOR DELIVERABLES
	  	 	8	  
			
	 6.0
	 	 PROGRAM MANAGEMENT
	  	 	9	  
			
	 7.0
	 	 [*]
	  	 	10	  
			
	 8.0
	 	 TECHNOLOGY TRANSFER
	  	 	11	  
			
	 9.0
	 	 PRODUCT RECOVERY AND PURIFICATION PROCESS TRANSFER
	  	 	11	  
			
	 10.0
	 	 ANALYTICAL METHOD
	  	 	13	  
			
	 11.0
	 	 DEMONSTRATION RUN
	  	 	14	  
			
	 12.0
	 	 [*] AND FACILITY PREPARATION
	  	 	15	  
			
	 13.0
	 	 [*]
	  	 	16	  
			
	 14.0
	 	 CGMP MANUFACTURING
	  	 	17	  
			
	 15.0
	 	 CURRENT PROCESS FLOW DIAGRAM
	  	 	19	  
			
	 16.0
	 	 CURRENT CERTIFICATE OF ANALYSIS FOR EGG WHITES
	  	 	20	  

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	Page 2 of 20

 SOW Technology Transfer and Manufacture of SBC-102 
  
  

	1.0	PROGRAM DEFINITIONS 

 The definitions
listed below reflect terms used in this Scope. 
  

			
	Sponsor:	  	Synageva BioPharm (Synageva) with a place of business at 128 Spring Street Suite 520 Lexington, MA 02421
		
	Fujifilm Diosynth:	  	Fujifilm Diosynth Biotechnologies USA Inc. (Fujifilm Diosynth), with a place of business at 101 J. Morris Commons Lane Morrisville, North Carolina 27560.
		
	Agreement:	  	The Bioprocessing Services Agreement, of which this Scope document is considered an attachment. (Also referred to herein as the “BSA”).
		
	Bulk Drug Substance:	  	Drug Substance filled into bulk containers, using aseptic techniques, under a laminar flow hood.
		
	cGMP:	  	Current Good Manufacturing Practices pursuant to (a) the U.S. Federal Food, Drug and Cosmetics Act as amended (21 USC 301 et seq.), (b) U.S. regulations in Title 21 of the U.S. Code
of Federal Regulations Parts 210, 211, 600 and 610 (c) the EC Guide to Good Manufacturing Practice for Medicinal Intermediate Products, v.4, including relevant sections of DIR 2003/94/EC, and (d) International Conference on Harmonization (ICH)
Guidance for Industry Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients.
		
	Drug Product:	  	The dosage form of SBC-102 in the final immediate packaging intended for clinical use.
		
	[*]:	  	[*] run intended to execute the series of unit operations, in the specified order to evaluate whether or not the process for manufacturing Product in its entirety meets Product /
process draft specifications.
		
	In-Process Control:	  	Analytical testing performed by Quality Control during execution of the process to provide data for making process decisions. The manufacturing process is on hold during
testing until results are obtained.
		
	In-Process Testing:	  	 Analytical testing performed on samples from the process, often after the process is finished, to provide data about performance
of the process.
  
 The manufacturing process is not on hold until results are
obtained. Results of In-Process Testing are not used for making decisions during execution of the process; but can be used for batch decisions after execution of the process.

		
	Item Specification:	  	A set of criteria to which a material must conform to be considered acceptable for its intended use.
		
	Intermediate	  	Process fraction containing Product generated during the manufacturing prior to Bulk Drug Substance.
		
	Manufacturing Process:	  	The detailed instructions used to produce the Product, which have been agreed by Fujifilm Diosynth and the Sponsor.
		
	Process Consumables:	  	Process Consumables include any Process Consumable or Raw Material used in the manufacture of an intermediate or Drug Substance that do not by themselves participate in a chemical
or biological reaction. Such other materials include: [*]
		
	Process:	  	The manufacturing process consisting of three sub-processes: fermentation, product recovery, and purification.

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	Page 3 of 20

 SOW Technology Transfer and Manufacture of SBC-102 
  

			
		
	Product:	  	Recombinant form of the human Lysosomal Acid Lipase (LAL) enzyme known as SBC-102
		
	Program:	  	The services to be performed with respect to Product by Fujifilm Diosynth under the Agreement as more particularly detailed in this Scope.
		
	Raw Materials:	  	Any ingredient intended for use in the manufacture of an intermediate or API, including those that may not appear in the final formulation. These include chemicals used directly
and/or indirectly in the manufacturing process.
		
	Reference Standard:	  	A substance that has been shown by an extensive set of analytical tests to be authentic material representative of the Product and process.
		
	Scope:	  	This Appendix 1 – Scope of work, which the Parties acknowledge is part of the Agreement. The scope is a component of the legal Agreement that specifies the Program design,
information desired, estimated duration of the Program and all other matters pertinent to the completion of the Program.
		
	Scope Assumptions:	  	Assumptions relating to the Program design, objectives, process assumptions, deliverables, resource requirements, timing, capital expenditure requirements (if any) and other matters
relating to the completion of the Program as set forth in the Scope.
		
	 Technical
 Summary

Report:
	  	Detailed reports to be provided to Synageva upon completion of the different sections of the Scope of work as detailed in Appendix 1 describing the experimental methods and
justification for the process description, to include data from all experiments, and a preliminary rationale for each unit operation. The reports will also outline any additional work that needs to be performed to complete the Process and Product
characterization and recommendations for the next stages, as appropriate.
		
	Third Party:	  	Any organization other than Fujifilm Diosynth and Sponsor, selected by Fujifilm Diosynth or Sponsor to perform services related to manufacture and testing of the
Product.

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	Page 4 of 20

 SOW Technology Transfer and Manufacture of SBC-102 
  
  

	2.0	ACRONYMS 

  

			
	API	  	Active Pharmaceutical Ingredient
		
	BDS	  	Bulk Drug Substance
		
	BLA	  	Biologics License Application
		
	BOM	  	Bill of Materials
		
	BSA	  	Bioprocessing Services Agreement
		
	C of A	  	Certificate of Analysis
		
	cGMP	  	current Good Manufacturing Practice
		
	CMC	  	Chemistry, Manufacturing and Controls
		
	CPL	  	Customer Project Leader
		
	DNA	  	Deoxyribonucleic Acid
		
	ELISA	  	Enzyme Linked Immuno-Sorbent Assay
		
	FDA	  	Food and Drug Administration
		
	HCP	  	Host Cell Protein
		
	HPLC	  	High Pressure Liquid Chromatography
		
	ICH	  	International Conference on Harmonization
		
	IPC	  	In-Process Control
		
	IPT	  	In-Process Test
		
	L	  	Liters
		
	QA	  	Quality Assurance
		
	QC	  	Quality Control
		
	SDS-PAGE	  	Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis
		
	SEC	  	Size Exclusion Chromatography
		
	SOP	  	Standard Operating Procedure
		
	STM	  	Standard Test Method
		
	TOC	  	Total Organic Carbon
		
	UF/DF	  	Ultrafiltration and Diafiltration

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	Page 5 of 20

 SOW Technology Transfer and Manufacture of SBC-102 
  
  

	3.0	INTRODUCTION 

 The Sponsor has requested
that Fujifilm Diosynth transfer the process and associated analytics for manufacture of SBC-102. SBC-102 is an enzyme replacement therapy for Lysosomal Acid Lipase (LAL) Deficiency, a lysosomal storage disorder. SBC-102 is a recombinant form of the
human LAL enzyme. SBC-102 contains glycan structures that are specifically recognized and internalized by specific receptors into key target cells. In 2010, SBC-102 received orphan drug designation in both the US and EU. 

SBC-102 is produced in the egg white of transgenic hens. SBC-102 will be recovered from the egg whites and purified. Synageva would like to establish a
process that is capable of processing approximately [*] of egg whites containing Lysosomal Acid Lipase (rhLAL) at Fujifilm Diosynth. At this time, Synageva is requesting [*] manufacturing runs at the scale of [*] egg whites. The first manufacturing
run may be executed as [*] 
  

	Note:	The ability to execute the [*] run is subject to business and quality agreement. An assessment of whether the [*] will be [*] run will be performed
after the conclusion of the [*]. 

 This Scope outlines activities for this program. 

TECHNOLOGY TRANSFER 

Process Transfer 
  

	 	•	 	 Product recovery process transfer 

  

	 	•	 	 Purification process transfer 

 Analytical 
  

	 	•	 	 Qualified method transfer to support technology transfer and manufacturing 

 Demonstration Runs 
  

	 	•	 	 [*] product recovery and purification runs to be executed at approximately [*] of egg whites containing rhLAL in the process development laboratories.
The actual volume of egg whites containing rhLAL will be determined based upon equipment and process scale factors. 

 MANUFACTURING 
 [*] 

 

	 	•	 	 Procurement and testing of raw materials and process consumables 

 

	 	•	 	 [*] and facility set-up, including qualification of necessary equipment, if required. 

cGMP Manufacturing Runs 
  

	 	•	 	 [*] at approximately [*] of egg whites containing rhLAL working scale. 

 

	 	•	 	 Disposition of all lots of SBC-102 drug substance produced. 

 

	Note:	 The ability to execute the [*] manufacturing run as a [*] run is subject to business and quality agreement. After reviewing the results of the
demonstration runs, the feasibility of the [*] manufacturing run to be executed as a [*] will be evaluated. If it is mutually agreed that the first manufacturing run will be executed as a [*], prior to execution of the run, both parties will agree
to target success criteria for the run. In the event the target 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	Page 6 of 20

 SOW Technology Transfer and Manufacture of SBC-102 
  

	 	
success criteria for the first are not met, the first run will be deemed an [*] and the Sponsor will be charged the [*] rate. Adjustments to the Scope, Price, and Payment Schedule will be
managed via Change Order. 

 Summary Reports 

 

	 	•	 	 Technology transfer activities summary report. 

  

	 	•	 	 Manufacturing activities summary report. 

  

	4.0	SCOPE ASSUMPTIONS 

 Assumptions for this
Scope are listed below. If these Scope Assumptions change or prove to be invalid, the Program activities, Program price, and estimated duration will be modified accordingly. 

 

	 	1.	Any timeline provided is for planning purposes only and exhibits estimated durations for activities. Any delay to contract approval and/or Sponsor deliverables may
subsequently delay other activities, including milestone completion dates. 

  

	 	2.	All technology transferred to Fujifilm Diosynth by Sponsor will perform as represented by Sponsor and is suitable for its intended use. 

 

	 	3.	All analytical samples collected during manufacturing will be stable under conditions recommended, to permit in process control testing. 

 

	 	4.	[*]. 

  

	 	5.	Standard Fujifilm Diosynth cleaning procedures are capable of degrading Product as demonstrated by [*]. 

 

	 	6.	Any animal derived materials that are required for Product production have been evaluated for TSE / BSE risk and deemed suitable for human use.

  

	 	7.	The majority of the manufacturing process can be modified to fit equipment currently available at Fujifilm Diosynth. Processing steps that may require capital
investment are the egg white thaw and the UFDF steps. A more detailed review of the program’s equipment needs will be evaluated during the transfer. [*], the program price and timeline may be impacted. 

 

	 	8.	Fujifilm Diosynth will employ [*] during performance of this Program as long as the equipment meets process requirements and appropriate cleaning and lack of carry-over
from other products can be demonstrated. Where appropriate Fujfilm Diosynth will employ [*] to support manufacturing of SBC-102. The final equipment list is dependent on the manufacturing scale and will be established during transfer and [*]. If
Synageva wishes to employ equipment [*] the manufacturing of SBC-102, or should [*] be required, the program price and timeline may be impacted. 

  

	 	9.	[*] will be used for storage of buffers and in-process materials as appropriate. Fujifilm Diosynth will leverage existing stability information (e.g. bioburden,
endotoxin) to support length of storage for process buffers and/or solutions. 

  

	 	10.	Product recovery can be completed within [*], including cleaning. 

  

	 	11.	Purification can be completed within [*], including awaiting QC eluate fraction results, cleaning and steaming. 

 

	 	12.	Low-pressure [*] chromatography columns will be used for purification. 

  

	 	13.	Sponsor will be responsible for performing any assays requiring the use of tissue cultures or animals. 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	Page 7 of 20

 SOW Technology Transfer and Manufacture of SBC-102 
  
  

	 	14.	Whenever possible, Raw Materials will be sourced as [*] from Fujifilm Diosynth approved vendors. Raw Materials will be released based on [*] C of A and ID testing only,
with the exception of Critical Raw Materials which will be [*]. 

  

	 	15.	[*] manufacturing runs at the [*] egg white scale are identified within the Scope. [*] of egg whites contains approximately [*]. At least [*] of the [*] manufacturing
runs will be executed under [*] conditions. 

 Note: The ability to execute the first
manufacturing run [*] run is subject to business and quality agreement. 
  

	 	16.	The Sponsor will be responsible for all [*]. 

  

	 	17.	Fujifilm Diosynth will use standard packing procedures for Product shipments. 

 

	 	18.	Fujifilm Diosynth’s standard formats will be used for preparation of transfer and manufacturing documentation. 

 

	5.0	SPONSOR DELIVERABLES 

 Sponsor will
provide the following items at the following times: 
 Lysosomal Acid Lipase (rhLAL) Egg Whites 

 

	 	1.	All egg whites containing Lysosomal Acid Lipase (rhLAL) provided to Fujifilm Diosynth must be tested and found negative for [*]. Documentation to ensure that the
material meets all agreed Certificate of Analysis specifications no less than [*] prior shipment of the material to Fujifilm Diosynth. 

  

	 	2.	Lysosomal Acid Lipase (rhLAL) containing egg whites, sufficient to initiation transfer activities, will be delivered to Fujifilm Diosynth Process Development
laboratories at least [*] prior to the start date for activities stated within the Scope. 

  

	 	3.	Lysosomal Acid Lipase (rhLAL) containing egg whites for cGMP production will be delivered to Fujifilm Diosynth upon establishment of the receiving [*] in support of
manufacturing activities. 

  

	 	4.	Documentation to support receipt, acceptance, and release of Lysosomal Acid Lipase (rhLAL) containing egg whites in accordance to the receiving [*] for use in the
manufacturing facility. 

 Analytical 
  

	 	5.	Analytical test methods, qualification or validation protocols and reports for the methods to be transferred, and list of reagents required within [*] of the effective
date of the Agreement. 

  

	 	6.	Qualified reference standard to support process transfer and demonstration run within [*] of the effective date of the Agreement. 

Process 
  

	 	7.	Documentation to initiate transfer and establishment of the manufacturing process (including process development reports, historical data, current process
specifications, list of materials and process consumables, and executed formulation and batch records or production protocols) – not to exceed [*] of the effective date of the Agreement. 

 

	 	8.	Bill of materials for GMP manufacturing with vendor catalogue numbers, material grade, and quantities for all process consumables – not to exceed [*] of the
effective date of the Agreement. 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	Page 8 of 20

 SOW Technology Transfer and Manufacture of SBC-102 
  
 Other 
  

	 	9.	Appointment of Alliance Manager authorized to represent and communicate with Fujifilm Diosynth on behalf of Sponsor. 

 

	 	10.	Timely review and approval of all Fujifilm Diosynth documents submitted to Sponsor for approval, such as [*] and Sponsor-[*] (preferably within [*]). Review of
documentation will be [*]. Comments from [*], if applicable, are to be provided cumulatively in one (1) document. 

  

	 	11.	MSDS and [*] regarding the Product in support of [*] of the Product [*] prior to initiation of process transfer activities. 

 

	 	12.	Timely updates on any results of [*], or otherwise acquired knowledge that might impact the [*]. 

 

	6.0	PROGRAM MANAGEMENT 

  

	6.1	Objectives 

  

	 	1.	Fujifilm Diosynth will provide overall management of the Program according to the Scope and Agreement. 

 

	6.2	Activities 

  

	 	1.	Fujifilm Diosynth will appoint a [*] to manage Program execution who will continuously evaluate the Program performance and will initiate discussions with Sponsor when
Program-related issues arise. 

  

	 	2.	The [*] will: 

  

	 	•	 	 Manage Program performance as defined in the Agreement. 

 

	 	•	 	 Serve as primary contact for the Program and communications with Sponsor and internal Fujifilm Diosynth project team members.

  

	 	•	 	 [*] work with Sponsor to determine what additional activities are required to support Sponsor’s Program and/or regulatory submissions.

  

	 	•	 	 [*] work with Sponsor to identify [*] Scope as defined, and determine and agree upon course of action according to the Agreement.

  

	 	•	 	 Conduct project meetings with Sponsor on a regular basis. Method of meeting (face-to-face, teleconference, etc.) and timing will be [*] and may vary
depending on the needs of the Program and provide appropriate documentation and reporting to the team [*]. 

  

	 	•	 	 Track Program progress against [*] 

  

	 	•	 	 Facilitate the review and approve invoices with the Sponsor. 

 

	6.3	[*] 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	Page 9 of 20

 SOW Technology Transfer and Manufacture of SBC-102 
  
  

	7.0	[*] 

  

	7.1	Objective 

  

	 	1.	Perform [*]. 

  

	 	2.	Establish requirements for [*]. 

  

	 	3.	Perform [*]: 

  

	 	•	 	 [*] requirements 

  

	 	•	 	 [*] requirements 

  

	Note:	[*] is required for all products [*]. [*] must be performed before any [*] 

 

	7.2	Activities 

  

	 	1.	Review Sponsor process of [*]. 

  

	 	2.	Review Sponsor supplied MSDS and [*] data to [*]. 

  

	 	3.	Establish [*]. 

  

	 	4.	Review [*] procedures for [*] and establish [*] requirements, if appropriate. 

 

	 	5.	Perform [*] to assess [*] of Product and [*]. 

  

	Note:	The joint project team will define the requirements of [*] for Product samples from [*]. 

 

	 	6.	Establish [*] requirements and recommend [*] solutions to ensure product [*]. 

 

	 	7.	Establish appropriate procedures and policies. 

  

	 	8.	Establish [*] requirements. 

  

	7.3	[*] 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	Page 10 of 20

 SOW Technology Transfer and Manufacture of SBC-102 
  
 TECHNOLOGY TRANSFER 
  

	8.0	TECHNOLOGY TRANSFER 

  

	8.1	Objective 

  

	 	1.	Prepare Fujifilm Diosynth personnel and [*] to support transfer of the SBC-102 process into Fujifilm Diosynth’s [*]. 

 

	8.2	Activities 

  

	 	1.	Receive and review existing process and analytical information from Sponsor in the form of raw data, manufacturing instructions, historical data and process development
reports. 

  

	 	2.	Establish an initial process consumable list and order materials required to support process development activities. 

 

	 	3.	Based on process documentation provided by Sponsor, prepare [*] Fujifilm Diosynth’s manufacturing facility, including [*]. 

 

	8.3	[*] 

  

	9.0	PRODUCT RECOVERY AND PURIFICATION PROCESS TRANSFER 

  

	9.1	Objectives 

  

	 	1.	Transfer the Sponsor’s product recovery and purification processes into Fujifilm Diosynth’s [*]. 

 

	 	2.	Adapt current processes, as necessary, to assure fit with Fujifilm Diosynth manufacturing facilities and equipment. 

 

	9.2	Activities 

  

	 	1.	Perform [*] recovery and purification transfer runs using Lysosomal Acid Lipase (rhLAL) containing egg whites supplied by the Sponsor. The target initial volume for
each transfer [*] of egg whites. The initial volume for each transfer set will be finalized in the [*] to ensure that the [*] transfer runs yields information suitable to use in assessing the process and transfer. 

 

	 	•	 	 [*] 

  

	 	2.	Evaluate the suitability of the transferred process for scale-up and cGMP manufacturing at Fujifilm Diosynth’s RTP manufacturing facility.

  

	 	3.	Adapt, as necessary, unit operations to fit Fujifilm Diosynth’s manufacturing facilities and equipment. 

 

	 	4.	Test [*]. 

  

	 	5.	Determine [*] operations. 

  

	 	6.	Evaluate [*] in the analytical methods section. 

  

	 	7.	Test [*] to support cGMP manufacturing. 

  

	 	8.	Evaluate [*] during cGMP manufacturing. 

  

	 	9.	Generate [*] of transfer activities. 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	Page 11 of 20

 SOW Technology Transfer and Manufacture of SBC-102 
  
  

	9.3	[*] 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	Page 12 of 20

 SOW Technology Transfer and Manufacture of SBC-102 
  
  

	10.0	ANALYTICAL METHOD 

 In the case of method
transfer, the Sponsor has completed qualification or validation of product-specific methods to be used for cGMP purposes. Diosynth Fujifilm will review and analyze Sponsor provided method development/qualification/validation reports. Based upon the
documentation, Fujifilm Diosynth will [*] each method to be transferred. In the case of method verification, Fujifilm Diosynth will [*] for each method to be verified. Fujifilm Diosynth expects that no more than [*] runs are sufficient to
demonstrate that knowledgeable analysts can successfully execute a method [*]. [*] for each transfer/verification will be provided to the Sponsor and the transfer of a method [*]. If target acceptance criteria are not met during the execution of the
[*] during or after the execution of the transfer protocol. Once the method transfer/verification protocol is successfully executed, [*] for verified methods) will be prepared to support cGMP activities. 

Definitions used in this section include: 
  

	 	•	 	 Verify: Demonstrating that an USP compendial method, general Fujifilm Diosynth qualified or validated method or commercial testing kit (e.g.,
[*]) is suitable for use with the intended product. 

  

	 	•	 	 Implement: Application of a Sponsor’s method at Fujifilm Diosynth [*]. Successful implementation of the method will be documented in a [*]
at the completion of execution. 

  

	 	•	 	 In-Process Control (IPC): Manufacturing decisions are based on the results of in-process control assays (e.g. methods used to determine protein
concentration for column loading). 

  

	 	•	 	 In-Process Test (IPT): [*]. This test provides a check that the process operates [*], as identified by transfer package.

  

	10.1	Objective 

  

	 	1.	Transfer Sponsor’s analytical methods and verify methods for use with Product as outlined in Table 1. 

 

	10.2	Activities 

  

	 	1.	Transfer qualified analytical methods from Sponsor for cGMP In-Process Testing, In-Process Control, and Drug Substance / Drug Product release testing.

  

	 	2.	Implement analytical methods from Sponsor to [*]. 

  

	 	3.	Verify that compendial methods are suitable for the intended purpose, meeting USP requirements [*]. 

 

	 	4.	Verify [*]. 

  

	 	5.	Prepare Program specific [*]. 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	Page 13 of 20

 SOW Technology Transfer and Manufacture of SBC-102 
  
 Table 1. SBC-102 Analytical Methods 
  

							
	 Assay
	  	 Purpose
	  	 Application
 IPT: In Process Testing
 IPC: In Process
Control
 DS: Drug Substance

PD: Process Development
	  	 Activity

	[*]	  	Concentration	  	[*]	  	Transfer Qualified
Synageva Method
	[*]	  	Identity	  	[*]	  	Transfer Qualified
Synageva Method
	[*]	  	Potency	  	[*]	  	Transfer Qualified
Synageva Method
	[*]	  	Safety	  	[*]	  	Transfer Qualified
Synageva Method
	[*]	  	Quality	  	[*]	  	Verify Fujifilm Diosynth Method
	[*]	  	Safety	  	[*]	  	Verify Fujifilm Diosynth Method
	[*]	  	Safety	  	[*]	  	Verify Fujifilm Diosynth Method
	[*]	  	Purity	  	[*]	  	Implement Synageva Method
	[*]	  	Purity	  	[*]	  	Implement Synageva Method

  

	10.3	[*] 

  

	11.0	DEMONSTRATION RUN 

  

	11.1	Objectives 

  

	 	1.	To perform [*] product recovery and purification runs using Lysosomal Acid Lipase containing egg whites supplied by the Sponsor. The target initial volume for each
demonstration run is [*] of egg whites. The initial volume for each demonstration run will be finalized after the transfer runs to ensure that the [*] demonstration runs yields information suitable for assessing the process and scale-up.

  

	11.2	Activities 

  

	 	1.	Perform Product recovery. 

  

	 	2.	Perform purification of Product. 

  

	 	3.	Provide [*]. 

  

	 	4.	Analyze purified Product alongside the reference standard using a [*] release methods. 

 

	 	5.	Develop [*] parameters such as [*] and [*], and [*] as well as [*] Product specifications based on [*]. 

 

	 	6.	Review demonstration run results and [*] determine the appropriate and subsequent activities. 

 

	 	7.	Document demonstration run in [*] 

  

	11.3	[*] 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	Page 14 of 20

 SOW Technology Transfer and Manufacture of SBC-102 
  
 MANUFACTURING 
  

	12.0	[*] AND FACILITY PREPARATION 

  

	12.1	Objectives 

  

	 	1.	To [*]. 

  

	 	2.	To procure and release Process Consumables to be used in the manufacture of Product. 

 

	 	3.	To provide Quality Assurance and Quality Control support, as needed. 

  

	12.2	Activities 

 Documentation

  

	 	1.	Prepare and approve all necessary documentation, [*] for the manufacture of Product.  

 

	 	2.	Establish [*] for Product and prepare and approve Product [*]. 

  

	 	3.	Complete [*] changeover activities. 

Material Procurement and Testing 
  

	 	4.	Perform a quality audit of [*] suppliers of process materials including the rhLAL containing egg whites. 

 

	 	5.	Procure, sample, test, and disposition Process Consumables to be utilized according to existing [*]. 

 

	 	6.	Test [*] from Fujifilm Diosynth-approved vendors as per Fujifilm Diosynth procedures. 

 

	 	7.	Perform sampling and submission of samples for testing to be [*], if necessary. 

 Notes: 
  

	•	 	 Fujifilm Diosynth will acquire and release Process Consumables for an anticipated cGMP manufacturing campaign and [*]. Where possible, Fujifilm
Diosynth will purchase [*] of a Process Consumable from approved vendor to [*]. Fujifilm Diosynth will procure Process Consumables for: 

  

	 	•	 	 [*] complete manufacturing runs ([*] egg white scale). 

 

	 	•	 	 [*] complete [*] run. 

  

	•	 	 Where Fujifilm Diosynth [*] are not available, the assay methods for testing the materials may require development and qualification [*].

  

	•	 	 Development and qualification of additional test methods for Raw Materials, if required, [*]. 

Set-up & Changeover 
  

	 	8.	Prepare facilities necessary for execution of the manufacturing processes including [*]. 

 

	 	9.	Confirm [*] status and perform [*] as necessary. 

  

	 	10.	Set-up all equipment necessary for execution of the process and testing. 

  

	 	11.	Prepare and set-up software, as necessary. 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	Page 15 of 20

 SOW Technology Transfer and Manufacture of SBC-102 
  
  

	12.3	[*] 

  

	13.0	[*] 

  

	13.1	Objectives 

  

	 	1.	To execute an [*] consisting of the product recovery, and purification units of operation. These runs will verify [*] with manufacturing equipment. This run will be
performed using [*] Process Consumables and [*] manufacturing suites, [*]. 

  

	 	2.	To provide available purified Product to Sponsor 

  

	 	3.	To test and correct any documentation [*]. 

  

	Note:	The [*] is a critical element to confirm successful scale-up of the process by providing the opportunity to execute all process steps on intended [*]
manufacturing equipment and to provide Fujifilm Diosynth manufacturing personnel hands on experience with the process. [*] is performed using [*] manufacturing documentation that is [*] operation. In the event of need for process modifications
during the [*], Fujifilm Diosynth will [*] and procedures, then [*]. [*] to the process flow may be necessary. Fujifilm Diosynth will [*] only for [*] of one or more of units of operations (e.g. a chromatography step.) Fujifilm Diosynth will inform
Sponsor of the modification as soon as possible. [*]. 

  

	13.2	Activities 

Manufacturing 
  

	 	1.	Perform the product recovery of approximately [*] of Lysosomal Acid Lipase (rhLAL) containing egg whites using [*]. 

 

	 	2.	Perform the purification of Product recovered from the [*] of Lysosomal Acid Lipase (rhLAL) containing egg whites using [*]. 

 

	 	3.	Collect samples for in-process testing according to [*]. 

  

	 	4.	Clean equipment and facilities, and [*]. 

  

	 	5.	Perform analytical testing [*] as required by the process. 

  

	 	6.	Complete and review [*] production records. 

  

	 	7.	Modify and update production records and submit [*]. 

  

	 	8.	Make equipment adjustments, if necessary, before [*] campaign. 

 Quality Control and [*] 
  

	 	9.	Perform in-process and release testing of Product produced from the [*] using [*] analytical documents. 

 

	 	10.	Perform environmental monitoring and testing of cleaning samples. 

 [*] 
  

	 	13.	Provide [*] oversight and support. 

  

	 	14.	Perform [*], if necessary. 

  

	 	15.	Evaluate [*]. 

  

	 	16.	Make [*] adjustments, if necessary, before [*] campaign. 

  

	 	17.	Host and provide [*]. 

 [*]

  

	 	18.	Provide [*], as needed. 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	Page 16 of 20

 SOW Technology Transfer and Manufacture of SBC-102 
  
  

	 	19.	Evaluate [*] manufacturing. 

  

	 	20.	Perform [*], if necessary. 

Quality Assurance 
  

	 	21.	Provide compliance oversight for use of cGMP facility. 

  

	 	22.	Review and approve modified and updated manufacturing documentation. 

  

	13.3	[*] 

  

	14.0	cGMP MANUFACTURING 

  

	14.1	Objectives 

  

	 	1.	To manufacture [*] of Product in accordance with cGMP and [*] manufacturing documentation. 

 

	 	2.	To provide Quality Assurance and Quality Control support as required. 

  

	 	3.	To support Sponsor’s regulatory filing by providing [*] pertaining to work performed at Fujifilm Diosynth. 

 

	Note:	The ability to execute the [*] is subject to business and quality agreement. After reviewing the results of the [*], the feasibility of the [*] will be
evaluated. If it is mutually agreed that the [*], prior to execution of the run, both parties will agree to [*]. In the event the [*] for the [*] will be deemed an [*] and the Sponsor will be [*]. Adjustments to the Scope, Price, and Payment
Schedule will be managed via Change Order. 

  

	14.2	Activities 

Manufacturing 
  

	 	1.	Perform [*] Product recoveries at [*] of Lysosomal Acid Lipase (rhLAL) containing egg whites using [*]. 

 

	 	2.	Perform [*] purification of Product using [*] 

  

	 	3.	Collect samples for in-process, release and stability testing according to [*]. 

 

	 	4.	Clean equipment and facilities, and [*]. 

  

	 	5.	Perform In-Process Control testing and/or In-Process Testing [*] as required by the process. 

 

	 	6.	Review executed production records. 

  

	 	7.	Participate in deviation closure and out-of-specification investigations, if any. 

Quality Control 
  

	 	8.	Perform In-Process Control testing for process steps according to [*]. 

  

	 	9.	Perform release testing according to Product [*]. 

  

	 	10.	Perform environmental monitoring and testing of cleaning samples. 

 [*] 
  

	 	11.	Provide [*] support as needed. 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	Page 17 of 20

 SOW Technology Transfer and Manufacture of SBC-102 
  
  

	 	12.	Perform [*], if necessary. 

  

	 	13.	Support [*] the process. 

  

	 	14.	Support [*]. 

  

	 	15.	Host and provide [*]. 

  

	 	16.	Prepare [*]. 

 [*]

  

	 	17.	Provide [*], as necessary. 

  

	 	18.	Support [*] the process. 

  

	 	19.	Support [*]. 

  

	 	20.	Evaluate [*] in comparison to [*]. 

  

	 	21.	Perform [*], if necessary 

Quality Assurance 
  

	 	22.	Provide compliance oversight for cGMP manufacturing. 

  

	 	23.	Issue [*] records. 

  

	 	24.	Review [*] records. 

  

	 	25.	Lead deviation closure and out-of-specification investigations, if any. 

  

	 	26.	Disposition of Drug Substance to Sponsor in accordance with an established Quality Agreement specifying [*]. 

 

	 	27.	Issue a Certificate of Analysis for Drug Substance. 

 Regulatory support 
  

	 	28.	Prepare data and documents to support regulatory filing. 

  

	 	29.	Perform [*] Fujifilm Diosynth [*], defining Fujifilm Diosynth’s [*]. 

  

	 	30.	Maintain a copy [*] and updates/changes at Fujifilm Diosynth. 

  

	14.3	[*] 

 Note -
Quality Assurance will provide the batch packet to the client for release as per quality procedures. The batch packet consists of, but is not limited to, the following information. 

 

	•	 	 Completed disposition of manufactured product form 

 

	•	 	 Completed batch genealogy 

  

	•	 	 Completed and reviewed process records, including in-process results. 

 

	•	 	 Certificate of Analysis 

  

	•	 	 Facilities assessment memo 

  

	•	 	 Quest Trackwise deviation report 

  

	•	 	 Quest Trackwise restriction summary 

  

	•	 	 Copies of all closed deviations associated with the batch. 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	Page 18 of 20

 SOW Technology Transfer and Manufacture of SBC-102 
  
  

	15.0	CURRENT PROCESS FLOW DIAGRAM 

 Attached is
the Process Flow Diagram for the current process as represented by the Sponsor 
 [*] 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	Page 19 of 20

 SOW Technology Transfer and Manufacture of SBC-102 
  
  

	16.0	CURRENT CERTIFICATE OF ANALYSIS FOR EGG WHITES 

 Attached is the current Certificate of Analysis for the rhLAL containing Egg Whites. 
 [*]

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
		 	CONFIDENTIAL	  	Page 20 of 20

 FUJIFILM Diosynth Biotechnologies – Synageva BioPharma Corp. 

Clinical Material Manufacturing Quality Agreement 

 
 Table of Contents 

 

					
	 General Information
	  	 	2	  
	 Signatures
	  	 	3	  
	 Quality Responsibilities Table
	  	 	4	  
	 Attachments
	  	 	9	  
	 Attachment A – Release Documentation
	  	 	9	  
	 Attachment B – Master Documents
	  	 	9	  
	 Attachment C – Definitions
	  	 	9	  

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
	Confidential	 		  	1 of 10

 FUJIFILM Diosynth Biotechnologies – Synageva BioPharma Corp. 

Clinical Material Manufacturing Quality Agreement 

 
 General Information 

This Quality Agreement outlines the roles, responsibilities and time requirements with respect to the Quality Assurance of the Intermediate and/or Drug
Substance produced by FUJIFILM Diosynth Biotechnologies U.S.A., Inc. (referred to in this Quality Agreement as “Fujifilm Diosynth”) for Synageva BioPharma Corp. (here within known as “Sponsor”) and fulfils the requirements as
outlined in ICH Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients. In addition, Fujifilm Diosynth may perform [*] as outlined within the Agreement. The drug substance covered by this Quality Agreement is <Sebelepase
alfa SBC-102>. 
 The Quality Agreement is an appendix to the Bioprocessing Services Agreement (BSA) executed by Sponsor and Fujifilm
Diosynth. 
 Unless otherwise defined specifically in this Quality Agreement, all general terms used herein will be interpreted in accordance
with the definitions provided in the BSA. Any terms not so defined will be interpreted with the definitions so stated in ICH Q7 or 21 CFR Parts 210, 211, 600, & 610. 
 The Authorized Quality Representatives will resolve any disputes or conflicts relating to this Quality Agreement in a timely and equitable manner and in compliance with all applicable quality and
regulatory requirements. Such resolutions shall be [*] by the Authorized Quality Representatives of each company. If any issue remains unresolved for more than twenty (20) business days, the senior corporate Quality officials from each company
should be contacted to resolve this issue. In the event the parties fail to reach agreement on such issue within thirty (30) calendar days after notice is provided to the senior corporate Quality officials, then such dispute shall be resolved
according to the provisions as detailed in the BSA. 
 All communication affecting the contents of this Quality Agreement will be between the
Authorized Quality Representatives, as set forth below: 
  

			
	For Sponsor:	 	Mark Hazard, Quality Responsible Head
		
	For Fujifilm Diosynth:	 	David Patterson, Sr. Vice President, Quality Operations

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
	Confidential	 		  	2 of 10

 Signatures 
 Sponsor Authorized Quality Assurance Representative 
  

											
	By:	 	  
	 		 		 	Date:	 	  

		 	      (Signature)	 		 		 		 	
					
	Name:	 	Mark Hazard	 		 	Tel.:	 	706-286-8932
		 		 		 	Email:	 	[*]
						
	Address:	 	Synageva BioPharma Corp.	 		 		 		 	
		 	150 Ben Burton Rd	 		 		 		 	
		 	Bogart, Ga. 30622	 		 		 		 	

 Fujifilm Diosynth Authorized Quality Assurance Representative 

 

									
	By:	 	  
	 		 	Date:	 	  

		 	      (Signature)	 		 		 	
					
	Name:	 	David Patterson	 		 	Tel.:	 	919-337-4408
		 		 		 	Email:	 	[*]
					
	Address:	 	FUJIFILM Diosynth Biotechnologies U.S.A., Inc.	 		 		 	
		 	101 J. Morris Commons Lane	 		 		 	
		 	Morrisville, North Carolina, USA, 27560	 		 		 	

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
	Confidential	 		  	3 of 10

 Quality Responsibilities Table 

The responsible party is denoted by ü 

 

							
	  	 	 Description
	  	 Fujifilm Diosynth

(time frame)
	  	 Sponsor

(time frame)

		
	1	 	Compliance
				
		 	Operate under Current Good Manufacturing Practices pursuant to (a) the U.S. Federal Food, Drug and Cosmetics Act as amended (21 USC 301 et seq.), (b) U.S. regulations in Title 21 of
the U.S. Code of Federal Regulations Parts 210, 211, 600 and 610 (c) the EC Guide to Good Manufacturing Practice for Medicinal Products, v.4, including relevant sections of DIR 2003/94/EC, and (d) International Conference on Harmonization (ICH)
Guidance for Industry Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients.	  	 ü

(at all times)
	  	
				
		 	Renegotiate the Quality Agreement	  	 ü

(as required)
	  	 ü

(as required)

				
		 	Appoint an Authorized Quality Representative for resolution of disputes	  	 ü

(prior to approval of Quality Agreement)
	  	 ü

(prior to approval of Quality Agreement)

				
		 	Give notification in event of Authorized Quality Representative change	  	 ü

(as required)
	  	 ü

(as required)

		
	2	 	Regulatory
				
		 	Prepare and update Regulatory applications	  		  	ü
				
		 	Provide information, as requested, to keep submissions current	  	ü	  	
				
		 	Provide copies of [*] relevant to work Fujifilm Diosynth performs for review and comment prior to submission to the [*]	  		  	ü
				
		 	Provide comments on [*] section(s) prior to submission [*]	  	 ü

([*] after receipt)
	  	
				
		 	Provide updates of [*]	  		  	 ü

(all [*] relevant to Fujifilm Diosynth process work)

				
		 	Responsible for all reporting requirements with regard to manufacturing site registration that may be required to support Sponsor related activities	  	ü	  	
				
		 	Provide a Letter of Authorization (LOA) to reference site registration filing	  	 ü

(when requested)
	  	
				
		 	For clients with LOAs, provide [*]	  	ü	  	
		
	3	 	Audits
				
		 	3.1        Regulatory Inspections	  		  	
				
		 	Provide notification of Regulatory Audits with Sponsor product impact	  	 ü

[*]
	  	
				
		 	Provide all Sponsor related regulatory observation response	  	 ü

[*]
	  	
			
		 	3.2        Sponsor Audits – Entitled to one on-site GMP audit per [*] period	  	
				
		 	Provide Notification to schedule audit – not to exceed [*]	  		  	 ü

[*]

				
		 	Schedule and support annual Sponsor Audits	  	ü	  	

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
	Confidential	 		  	4 of 10

							
	  	 	 Description
	  	 Fujifilm Diosynth

(time frame)
	  	 Sponsor

(time frame)

				
		 	Provide written audit report	  		  	 ü

([*] from completion of audit)

				
		 	Provide written response to observations	  	 ü

([*] from receipt of observations)
	  	
				
		 	3.3        For Cause Audits	  		  	
				
		 	Provide notification to schedule For Cause Audit	  		  	 ü

(as required)

				
		 	Schedule and support For Cause Audit	  	 ü

(scheduled at a mutually agreed upon time)
	  	
				
	4	 	Complaint handling	  		  	
				
		 	Notify other party of any information coming into its possession concerning [*]	  	 ü

(within [*])
	  	 ü

(within [*])

				
		 	Participate in the development of investigation plans	  		  	 ü

([*] from Sponsor notification)

				
		 	Investigate the issue to the extent that it relates to Fujifilm Diosynth’s activities and provide a written report	  	 ü

(Target [*] from date event observed)
	  	
				
		 	 Approve Complaints
 [*]
	  	 ü

(Target [*] from date event observed)
	  	 ü

([*] from receipt of complaint summary)

				
		 	Determine how to address the information impacting the product quality and safety	  		  	ü
				
		 	Communicate with regulatory authorities	  		  	ü
				
	5	 	Change Management	  		  	
				
		 	Communicate need for change to approved master documents (as defined in Attachment B)	  	ü	  	ü
				
		 	Review proposed change for conformance to any regulatory commitments	  		  	 ü

([*] from receipt of change summary)

				
		 	Use [*] in controlled documents to track changes (review and approval according to Section 8)	  	ü	  	
				
		 	Use [*] for changes made to validated processes and/or systems	  	ü	  	
			
	6	 	Facilities, Equipment, and Utilities Validation and Qualification	  	
				
		 	Maintain the qualified and/or validated state of equipment, facilities, and utilities including equipment supporting [*]	  	 ü

(on-going)
	  	
				
	7	 	Consumables and Raw Materials	  		  	
				
		 	Determine suitable Process Consumables	  	ü	  	ü
				
		 	Determine sources for identified Process Consumables	  	ü	  	
				
		 	Develop and approve test methods for Raw Materials	  	ü	  	 ü

[*]

				
		 	Develop and approve [*] for Process Consumables	  	ü	  	 ü

[*]

				
		 	Approve suppliers of Process Consumables	  	ü	  	 ü

[*]

				
		 	Procure, store, sample and test Raw Materials according to approved [*]	  	ü	  	

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
	Confidential	 		  	5 of 10

							
	  	 	 Description
	  	 Fujifilm Diosynth

(time frame)
	  	 Sponsor

(time frame)

				
		 	Release Process Consumables prior to use	  	ü	  	
				
		 	 Audit supplier for [*] Process Consumables
 Provide summary of supplier audit to Fujifilm Diosynth
	  		  	 ü

(prior to receipt of material at Fujifilm Diosynth)

				
		 	Use only the Process Consumables that are listed in the approved master controlled documents [*]	  	ü	  	
				
		 	Review supplier changes for compliance with regulatory filings and notify Sponsor	  	ü	  	
				
		 	7.1        Animal Derived Materials	  		  	
				
		 	Source relevant Raw Materials from non-animal derived sources whenever possible	  	ü	  	
				
		 	Comply with U.S. and European regulations (EP, latest edition, Chapter 5.2.8, Minimizing the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Medicinal
Products)	  	ü	  	
				
		 	Obtain Country of Origin certification and confirm source country is not a known BSE-contaminated country (in accord with 9CFR94.18) or by ensuring the processing methods are known
to inactivate TSE agents, per CHMP guidelines	  	ü	  	
				
		 	Supply statement regarding process materials confirmed to be of animal origin as regards to TSE/BSE compliance and provide updates, as needed	  	 ü

(when requested)
	  	
		
	8	 	Master Batch Records, Product Specification(s), Test Methods and Qualification/Validation Documentation
				
		 	Author master documents (as defined in Attachment B)	  	 ü

(prior to start of first full scale run)
	  	
				
		 	Review master documents (as defined in Attachment B)	  	ü	  	 ü

(comments within [*] of receipt)

				
		 	Approve master documents (as defined in Attachment B)	  	ü	  	 ü

(approval within [*] of receipt)

				
		 	Revise master documents	  	 ü

(as required)
	  	
				
		 	Author transfer, qualification, and validations protocols	  	ü	  	
				
		 	 Review transfer, qualification, and validations protocols
 [*]
	  	ü	  	 ü

(comments within [*] of receipt)

				
		 	Approve, transfer, qualification, and validations protocols	  	ü	  	 ü

(approval within [*] of receipt)

				
		 	Execute transfer, development, qualification and/or validation (as defined within the Scope of Work)	  	ü	  	
				
		 	Author transfer, qualification, and validations summary reports	  	ü	  	
				
		 	 Review transfer, qualification, and validations summary reports

[*]
	  	ü	  	 ü

(comments within [*] of receipt)

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
	Confidential	 		  	6 of 10

							
	  	 	 Description
	  	 Fujifilm Diosynth

(time frame)
	  	 Sponsor

(time frame)

				
		 	Approve transfer, qualification, and validations summary reports	  	ü	  	 ü

(approval within [*] of receipt)

		
	9	 	Manufacturing and Packaging of DS and/or Intermediates
				
		 	The execution of manufacture, packaging, holding and labeling of DS in accordance with approved procedures	  	ü	  	
		
	10	 	Quality Control Testing to Support cGMP Manufacture
				
		 	Sample according to batch records or other approved document	  	ü	  	
				
		 	Test material using approved methods	  	ü	  	
				
		 	Compare results against Approved Specifications	  	ü	  	
		
	11	 	Deviations and Out-of-Specification Results
				
		 	Notification of Deviations with Potential Product Impact	  	 ü

([*] from Fujifilm Diosynth QA notification)
	  	
				
		 	Notification of Significant Deviations and/or confirmed Out of Specification (OOS) Results	  	([*] from Fujifilm Diosynth QA classification)	  	
				
		 	Participate in the development of investigation plans	  		  	 ü

([*] from Sponsor notification)

				
		 	Complete the investigation into Deviations or/and OOSs	  	 ü

([*] from date event observed, or prior to execution of next campaign)
	  	
				
		 	Approve Deviation and / or OOS	  	 ü

([*] from date event observed, or prior to execution of next campaign)
	  	
				
		 	 Approve Deviations with potential product impact and OOSs
 [*]
	  		  	 ü

([*] from receipt of deviation summary)

		
	12	 	Batch Disposition and Release
				
		 	Prepare a Batch Packet (as defined in Attachment A), providing [*] and OOSs are approved	  	 ü

([*] from date of manufacture)
	  	
				
		 	Disposition Intermediate and /or Drug Substance, providing [*] and OOSs are approved	  	 ü

([*] from date of manufacture)
	  	
				
		 	Release Intermediate and /or Drug Substance. Issue a Certificate of Conformance (COC), or similar	  		  	 ü

([*] from receipt of batch packet)

				
		 	Maintain original batch records	  	 ü

(minimum of [*])
	  	
				
		 	Make records [*]	  	 ü

(in a timeframe mutually agreed upon)
	  	
				
	13	 	Storage, Delivery and Shipment	  		  	
				
		 	Store materials under appropriate conditions	  	ü	  	
				
		 	Provide information on required shipping conditions	  		  	ü

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
	Confidential	 		  	7 of 10

							
	  	 	 Description
	  	 Fujifilm Diosynth

(time frame)
	  	 Sponsor

(time frame)

				
		 	Authorize delivery of released Intermediate and/or Drug Substance	  		  	ü
				
		 	Deliver released Intermediate and /or Drug Substance to Sponsor’s nominated courier	  	ü	  	
		
	14	 	Person-in-the-Plant
				
		 	Adhere to applicable Fujifilm Diosynth procedures	  		  	 ü

(at all times)

		
	15	 	QA Retain Samples of Intermediates and Drug Substance
				
		 	Store sufficient quantity ([*] amount needed for release testing, [*]) of QA Retain for the purposes of fulfilling the regulatory reserve requirement	  	 ü

(minimum of [*] from date of manufacture)
	  	
		
	16	 	Use of Subcontractors
				
		 	Use subcontractors that meet the requirements for Approved Suppliers	  	ü	  	
				
		 	Approve the use of subcontractors, prior to use, for testing [*]	  	ü	  	ü
				
		 	Through the use of Fujifilm Diosynth Quality systems, participate in any investigations and corrective actions that occur at the subcontractor	  	ü	  	ü
		
	17	 	Returned Goods
				
		 	Handle return materials using a cGMP compliant system	  	ü	  	
				
	18	 	 [*]
 (when applicable,
as detailed in the Scope)
	  		  	
				
		 	[*] using approved methods	  	ü	  	
				
		 	Compare results against approved specifications	  	ü	  	
				
		 	Issue a Certificate of Analysis	  	 ü

([*] from receipt of samples)
	  	
		
	19	 	 Stability Testing and Expiration Period
 (when applicable)

				
		 	Author stability protocols	  	ü	  	
				
		 	Review stability protocols	  	ü	  	 ü

(comments within [*] of receipt)

				
		 	Approve stability protocols	  	ü	  	 ü

(approval within [*] of receipt)

				
		 	Carry out stability program in accordance with approved protocols and ICH guidelines	  	ü	  	
				
		 	Test stability samples using approved methods	  	ü	  	
				
		 	Provide copies of results following each time point	  	 ü

([*] from completion of testing, not to exceed [*] from scheduled pull date)
	  	
				
		 	Establish Expiry or Retest Period	  		  	ü

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
	Confidential	 		  	8 of 10

 Attachments 
 Attachment A – Batch Packet Documentation 
 Relevant documentation to be transferred
to Sponsor to facilitate the release of a Batch. This packet consists of copies of: [*] 
 Attachment B – Master
Documents 
 Master Documents include: 
 Master Batch Records 
 Master Formulation Records 

Test Methods 

Forms 
 Item
Specifications 
 Stability Protocols 
 Qualification/Validation Documents 
 Master Documents requiring Sponsor [*] 

Attachment C – Definitions 
  

			
	API	  	Active Pharmaceutical Ingredient, may be used interchangeably with Drug Substance.
		
	Approved Supplier	  	A supplier who has met minimum approval standards and who has been approved to provide required items or services that may impact product quality.
		
	Authorized Quality Representatives	  	An individual named within the Quality Agreement with the authority to resolve any disputes or conflicts relating to this Quality Agreement in a timely and equitable manner and in
compliance with all applicable quality and regulatory requirements.
		
	Batch	  	A specific quantity of material produced in a process or fraction of a process. Batches are defined as the material represented at the end of the intermediate processing steps or
the material represented at the end of the processing step for API.
		
	cGMP	  	Current Good Manufacturing Practices pursuant to (a) the U.S. Federal Food, Drug and Cosmetics Act as amended (21 USC 301 et seq.), (b) U.S. regulations in Title 21 of the U.S. Code
of Federal Regulations Parts 210, 211, 600 and 610 (c) the EC Guide to Good Manufacturing Practice for Medicinal Products, v.4, including relevant sections of DIR 2003/94/EC, and (d) International Conference on Harmonization (ICH) Guidance for
Industry Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients.

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
	Confidential	 		  	9 of 10

			
		
	Critical Raw Materials	  	Raw materials comprise final formulation components and / or that combine structurally or chemically with the therapeutic protein.
		
	Deviation	  	An unplanned event requiring investigation which 1) may affect the quality or compliance status of the product, process materials, equipment or facility involved or 2) may not be in
alignment with regulatory submissions.
		
	Disposition	  	A recommendation given by Fujifilm Diosynth Quality on the suitability of the Intermediate or Drug Substance for further processing.
		
	Drug Product	  	The dosage form in the final immediate packaging intended for clinical use.
		
	Drug Substance or DS	  	Any substance or mixture of substances intended to be used in the manufacture of a drug (medicinal) product and that, when used in the production of a drug, becomes an active
ingredient of the Drug Product. Such substances are intended to furnish pharmacological activity or other direct effect on the diagnosis, cure mitigation, treatment, or prevention of disease or to affect the structure and function of the
body.
		
	Process Consumables	  	Process Consumables include any disposable equipment or equipment parts or Raw Material used in the manufacture of an intermediate or Drug Substance that do not themselves
participate in a chemical or biological reaction. Such other materials include: [*].
		
	Product	  	Any (a) API/Drug Substance, or (b) Drug Product comprised of API/Drug Substance, or (c) intermediate(s) of (a) or (b) , in each case as specified in the applicable
Scope.
		
	Raw Material	  	Any ingredient intended for use in the manufacture of an intermediate or API, including those that may not appear in the final formulation. These include chemicals used directly
and/or indirectly in the manufacturing process.
		
	Statement of Compliance	  	A Fujifilm Diosynth QA Disposition of Product Statement stating that a specific Batch of Drug Substance complies with all Product, GMP and regulatory requirements and is signed by
an authorized representative of Fujifilm Diosynth.
		
	Test Methods	  	Methods used for QC testing, including Standard Test Methods and Compendial Methods.

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

  

					
	Confidential	 		  	10 of 10

 Appendix 3 
 Synageva SBC-102 Program Price 
  

					
	 Activity
	  	Price	 
	 Technology Transfer
	  	 	[	*] 
	 [*]
	  	 	[	*] 
	 [*]
	  	 	[	*] 
	 Analytical Method Transfer
	  	 	[	*] 
	 Demonstration Runs ([*])
	  	 	[	*] 
	 [*]
	  	 	[	*] 
	 [*] Manufacturing ([*])
	  	 	[	*] 
	 cGMP [*] ([*])
	  	 	[	*] 
	 [*]
	  	 	[	*] 
	 TOTAL
	  	 	[	*] 

  

					
	 Optional Activity
	  	Price	 
	 [*]
	  	 	[	*] 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

 Synageva SBC-102 Payment Schedule 

 

													
	 Activity/Milestone
	  	Payment	 	 	Credit	 	 	Net Payment	 
	 [*]
	  	 	[	*] 	 				 	 	[	*] 
	 [*]
	  	 	[	*] 	 				 	 	[	*] 
	 [*]
	  	 	[	*] 	 				 	 	[	*] 
	 [*]
	  	 	[	*] 	 				 	 	[	*] 
	 [*]
	  	 	[	*] 	 				 	 	[	*] 
	 [*]
	  	 	[	*] 	 				 	 	[	*] 
	 [*]
	  	 	[	*] 	 				 	 	[	*] 
	 [*]
	  	 	[	*] 	 				 	 	[	*] 
	 [*]
	  	 	[	*] 	 				 	 	[	*] 
	 [*]
	  	 	[	*] 	 				 	 	[	*] 
	 [*]
	  	 	[	*] 	 				 	 	[	*] 
	 [*]
	  	 	[	*] 	 				 	 	[	*] 
	 [*]
	  	 	[	*] 	 				 	 	[	*] 
	 [*]
	  	 	[	*] 	 				 	 	[	*] 
	 [*]
	  	 	[	*] 	 	 	[	*] 	 	 	[	*] 
	 [*]
	  	 	[	*] 	 				 	 	[	*] 
	 [*]
	  	 	[	*] 	 				 	 	[	*] 
	 [*]
	  	 	[	*] 	 				 	 	[	*] 
	 [*]
	  	 	[	*] 	 	 	[	*] 	 	 	[	*] 
	 [*]
	  	 	[	*] 	 				 	 	[	*] 
	 [*]
	  	 	[	*] 	 				 	 	[	*] 
	 [*]
	  	 	[	*] 	 	 	[	*] 	 	 	[	*] 
	 [*]
	  	 	[	*] 	 				 	 	[	*] 
	 [*]
	  	 	[	*] 	 				 	 	[	*] 
	 [*]
	  	 	[	*] 	 	 	[	*] 	 	 	[	*] 
	 [*]
	  	 	[	*] 	 				 	 	[	*] 
	 TOTAL
	  				 	 	[	*] 	 	 	[	*] 

  

					
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the
Securities and Exchange Commission.

 -2-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00216-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00216-of-00352.parquet"}]]